hydrazide - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	hydrazide	go back to main search page
Accession:	CHEBI:35362	browse the term
Definition:	Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
Synonyms:	related_synonym:	hydrazides

show annotations for term's descendants Sort by:
Rat (1138) Mouse (1151) Human (1160) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (1138)

acetohydrazide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

anillin, actin binding protein

decreases expression

acetylhydrazine results in decreased expression of ANLN mRNA

NCBI chr 8:20,858,227...20,921,602
Ensembl chr 8:20,858,228...20,921,538

G

adaptor related protein complex 1 subunit sigma 3

decreases expression

acetylhydrazine results in decreased expression of AP1S3 mRNA

NCBI chr 9:80,950,402...81,009,889
Ensembl chr 9:80,950,715...81,009,798

G

ADP-ribosyltransferase 5

decreases expression

acetylhydrazine results in decreased expression of ART5 mRNA

NCBI chr 1:156,473,362...156,483,324
Ensembl chr 1:156,473,362...156,483,324

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1

decreases expression

acetylhydrazine results in decreased expression of ATP2A1 mRNA

NCBI chr 1:181,026,606...181,044,859
Ensembl chr 1:181,026,608...181,044,838

G

C-C motif chemokine ligand 22

decreases expression

acetylhydrazine results in decreased expression of CCL22 mRNA

NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400

G

Cd28 molecule

decreases expression

acetylhydrazine results in decreased expression of CD28 mRNA

NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685

G

CD79b molecule

decreases expression

acetylhydrazine results in decreased expression of CD79B mRNA

NCBI chr10:91,239,354...91,242,500
Ensembl chr10:91,239,356...91,242,625

G

CUGBP, Elav-like family member 1

decreases expression

acetylhydrazine results in decreased expression of CELF1 mRNA

NCBI chr 3:76,924,591...76,999,429
Ensembl chr 3:76,924,613...76,999,426

G

claudin 8

decreases expression

acetylhydrazine results in decreased expression of CLDN8 mRNA

NCBI chr11:27,875,857...27,878,106
Ensembl chr11:27,875,692...27,878,513

G

chymase 1

decreases expression

acetylhydrazine results in decreased expression of CMA1 mRNA

NCBI chr15:29,417,451...29,420,233
Ensembl chr15:29,417,451...29,420,233

G

collagen type XI alpha 1 chain

decreases expression

acetylhydrazine results in decreased expression of COL11A1 mRNA

NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853

G

cytochrome P450, family 51

increases expression

acetylhydrazine results in increased expression of CYP51 mRNA

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
Ensembl chr 6:30,036,865...30,055,410

G

delta like canonical Notch ligand 1

decreases expression

acetylhydrazine results in decreased expression of DLL1 mRNA

NCBI chr 1:56,312,062...56,320,177
Ensembl chr 1:56,312,066...56,320,179

G

distal-less homeobox 5

decreases expression

acetylhydrazine results in decreased expression of DLX5 mRNA

NCBI chr 4:34,999,139...35,003,504
Ensembl chr 4:34,999,139...35,003,407

G

ephrin B3

decreases expression

acetylhydrazine results in decreased expression of EFNB3 mRNA

NCBI chr10:54,274,506...54,281,951
Ensembl chr10:54,274,506...54,280,471

G

fibroblast growth factor 14

decreases expression

acetylhydrazine results in decreased expression of FGF14 mRNA

NCBI chr15:101,045,033...101,679,888
Ensembl chr15:101,045,036...101,679,900

G

fibrinogen-like 2

decreases expression

acetylhydrazine results in decreased expression of FGL2 mRNA

NCBI chr 4:13,710,566...13,716,207
Ensembl chr 4:13,710,575...13,716,207

G

GTPase, IMAP family member 7

decreases expression

acetylhydrazine results in decreased expression of GIMAP7 mRNA

NCBI chr 4:77,670,522...77,674,692
Ensembl chr 4:77,670,367...77,675,272

G

glutamate receptor interacting protein 1

decreases expression

acetylhydrazine results in decreased expression of GRIP1 mRNA

NCBI chr 7:54,934,856...55,592,274
Ensembl chr 7:54,934,250...55,592,273

G

hemogen

decreases expression

acetylhydrazine results in decreased expression of HEMGN mRNA

NCBI chr 5:60,679,633...60,698,597
Ensembl chr 5:60,679,633...60,698,669

G

homeo box B6

decreases expression

acetylhydrazine results in decreased expression of HOXB6 mRNA

NCBI chr10:81,258,726...81,267,458
Ensembl chr10:81,265,056...81,267,449

G

immunoglobulin heavy constant gamma 1

decreases expression

acetylhydrazine results in decreased expression of IGHG1 mRNA

Ensembl chr 6:132,389,370...132,393,397

G

IL2-inducible T-cell kinase

decreases expression

acetylhydrazine results in decreased expression of ITK mRNA

NCBI chr10:30,753,344...30,814,685
Ensembl chr10:30,753,344...30,814,685

G

junctional adhesion molecule 3

decreases expression

acetylhydrazine results in decreased expression of JAM3 mRNA

NCBI chr 8:25,508,461...25,569,306
Ensembl chr 8:25,507,057...25,569,355

G

potassium calcium-activated channel subfamily N member 4

decreases expression

acetylhydrazine results in decreased expression of KCNN4 mRNA

NCBI chr 1:79,956,380...79,974,354
Ensembl chr 1:79,959,322...79,974,340

G

kinesin family member 22

decreases expression

acetylhydrazine results in decreased expression of KIF22 mRNA

NCBI chr 1:181,635,347...181,650,351
Ensembl chr 1:181,635,183...181,650,401

G

kinesin family member 4A

decreases expression

acetylhydrazine results in decreased expression of KIF4 mRNA

NCBI chr X:65,721,746...65,824,277
Ensembl chr X:65,721,779...65,824,139

G

KRIT1, ankyrin repeat containing

increases expression

acetylhydrazine results in increased expression of KRIT1 mRNA

NCBI chr 4:30,299,203...30,333,366
Ensembl chr 4:30,299,203...30,333,359

G

LCK proto-oncogene, Src family tyrosine kinase

decreases expression

acetylhydrazine results in decreased expression of LCK mRNA

NCBI chr 5:141,888,318...141,916,945
Ensembl chr 5:141,888,326...141,903,794

G

leptin receptor

decreases expression

acetylhydrazine results in decreased expression of LEPR mRNA

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

galectin 1

increases expression

acetylhydrazine results in increased expression of LGALS1 mRNA

NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345

G

leucine rich repeat neuronal 1

decreases expression

acetylhydrazine results in decreased expression of LRRN1 mRNA

NCBI chr 4:140,476,752...140,520,210
Ensembl chr 4:140,476,324...140,518,620

G

leukotriene C4 synthase

decreases expression

acetylhydrazine results in decreased expression of LTC4S mRNA

NCBI chr10:34,560,476...34,562,790
Ensembl chr10:34,560,360...34,562,651

G

microtubule-associated protein 6

decreases expression

acetylhydrazine results in decreased expression of MAP6 mRNA

NCBI chr 1:153,568,020...153,634,415
Ensembl chr 1:153,568,368...153,634,414

G

mitogen activated protein kinase 10

decreases expression

acetylhydrazine results in decreased expression of MAPK10 mRNA

NCBI chr14:6,497,662...6,790,109
Ensembl chr14:6,497,707...6,786,201

G

minichromosome maintenance 9 homologous recombination repair factor

decreases expression

acetylhydrazine results in decreased expression of MCM9 mRNA

NCBI chr20:32,818,219...32,929,577
Ensembl chr20:32,844,951...32,929,600

G

matrix Gla protein

decreases expression

acetylhydrazine results in decreased expression of MGP mRNA

NCBI chr 4:169,766,290...169,769,612
Ensembl chr 4:169,766,279...169,769,667

G

major intrinsic protein of lens fiber

decreases expression

acetylhydrazine results in decreased expression of MIP mRNA

NCBI chr 7:643,502...653,121
Ensembl chr 7:647,315...654,400

G

myeloperoxidase

multiple interactions
increases oxidation

[MPO protein results in increased oxidation of acetylhydrazine] which results in increased chemical synthesis of Free Radicals

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

metallothionein 1

increases expression

acetylhydrazine results in increased expression of MT1 mRNA

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049
Ensembl chr X:10,826,032...10,827,049

G

mevalonate diphosphate decarboxylase

increases expression

acetylhydrazine results in increased expression of MVD mRNA

NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971

G

myosin binding protein H

decreases expression

acetylhydrazine results in decreased expression of MYBPH mRNA

NCBI chr13:45,653,156...45,660,893
Ensembl chr13:45,653,234...45,660,893

G

MYC proto-oncogene, bHLH transcription factor

decreases expression

acetylhydrazine results in decreased expression of MYC mRNA

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

NEDD8 ubiquitin like modifier

decreases expression

acetylhydrazine results in decreased expression of NEDD8 mRNA

NCBI chr15:29,153,556...29,165,575
Ensembl chr15:29,153,556...29,166,160

G

outer dense fiber of sperm tails 1

decreases expression

acetylhydrazine results in decreased expression of ODF1 mRNA

NCBI chr 7:69,377,427...69,389,662
Ensembl chr 7:69,380,116...69,389,664

G

outer dense fiber of sperm tails 2

decreases expression

acetylhydrazine results in decreased expression of ODF2 mRNA

NCBI chr 3:13,160,981...13,207,223
Ensembl chr 3:13,161,494...13,206,985

G

proprotein convertase subtilisin/kexin type 9

increases expression

acetylhydrazine results in increased expression of PCSK9 mRNA

NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688

G

programmed cell death 11

decreases expression

acetylhydrazine results in decreased expression of PDCD11 mRNA

NCBI chr 1:245,980,840...246,021,999
Ensembl chr 1:245,980,880...246,021,999

G

proliferation and apoptosis adaptor protein 15

decreases expression

acetylhydrazine results in decreased expression of PEA15 mRNA

NCBI chr13:84,657,815...84,667,437
Ensembl chr13:84,654,870...84,667,499

G

PHD finger protein 6

decreases expression

acetylhydrazine results in decreased expression of PHF6 mRNA

NCBI chr X:132,656,658...132,699,720
Ensembl chr X:132,656,672...132,699,127

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma

decreases expression

acetylhydrazine results in decreased expression of PIK3CG mRNA

NCBI chr 6:48,766,778...48,802,098
Ensembl chr 6:48,766,864...48,802,043

G

paired immunoglobin-like type 2 receptor alpha

increases expression

acetylhydrazine results in increased expression of PILRA mRNA

NCBI chr12:17,787,169...17,798,149
Ensembl chr12:17,787,127...17,798,094

G

phospholipase A and acyltransferase 1

decreases expression

acetylhydrazine results in decreased expression of PLAAT1 mRNA

NCBI chr11:71,517,492...71,537,142
Ensembl chr11:71,517,493...71,527,020

G

DNA polymerase gamma, catalytic subunit

decreases expression

acetylhydrazine results in decreased expression of POLG mRNA

NCBI chr 1:133,382,764...133,399,578
Ensembl chr 1:133,382,766...133,398,567

G

sodium voltage-gated channel alpha subunit 3

decreases expression

acetylhydrazine results in decreased expression of SCN3A mRNA

NCBI chr 3:50,146,411...50,258,119
Ensembl chr 3:50,148,139...50,258,119

G

semaphorin 5A

decreases expression

acetylhydrazine results in decreased expression of SEMA5A mRNA

NCBI chr 2:83,309,843...83,741,084
Ensembl chr 2:83,309,843...83,741,084

G

SPARC/osteonectin, cwcv and kazal like domains proteoglycan 3

decreases expression

acetylhydrazine results in decreased expression of SPOCK3 mRNA

NCBI chr16:26,382,895...26,815,943
Ensembl chr16:26,383,383...26,815,205

G

spectrin, beta, non-erythrocytic 1

decreases expression

acetylhydrazine results in decreased expression of SPTBN1 mRNA

NCBI chr14:103,841,713...104,016,900
Ensembl chr14:103,842,684...104,008,507

G

syntaxin binding protein 1

decreases expression

acetylhydrazine results in decreased expression of STXBP1 mRNA

NCBI chr 3:16,076,725...16,138,431
Ensembl chr 3:16,076,391...16,138,369

G

TRAF2 and NCK interacting kinase

decreases expression

acetylhydrazine results in decreased expression of TNIK mRNA

NCBI chr 2:111,184,352...111,587,993
Ensembl chr 2:111,184,387...111,580,750

G

thyroid hormone receptor interactor 13

decreases expression

acetylhydrazine results in decreased expression of TRIP13 mRNA

NCBI chr 1:29,357,093...29,402,078
Ensembl chr 1:29,357,130...29,402,074

G

ubiquitin-conjugating enzyme E2, J2

decreases expression

acetylhydrazine results in decreased expression of UBE2J2 mRNA

NCBI chr 5:166,533,374...166,547,811
Ensembl chr 5:166,533,418...166,547,804

G

ubiquitin specific peptidase 15

decreases expression

acetylhydrazine results in decreased expression of USP15 mRNA

NCBI chr 7:58,756,714...58,848,778
Ensembl chr 7:58,756,872...58,848,721

G

vav guanine nucleotide exchange factor 2

decreases expression

acetylhydrazine results in decreased expression of VAV2 mRNA

NCBI chr 3:10,584,688...10,754,128
Ensembl chr 3:10,584,688...10,754,052

G

VPS54 subunit of GARP complex

decreases expression

acetylhydrazine results in decreased expression of VPS54 mRNA

NCBI chr14:95,378,821...95,455,871
Ensembl chr14:95,378,012...95,455,857

G

zinc finger protein 334

decreases expression

acetylhydrazine results in decreased expression of ZFP334 mRNA

NCBI chr 3:154,112,537...154,125,087
Ensembl chr 3:154,113,561...154,125,057

G

zinc finger protein 91

decreases expression

acetylhydrazine results in decreased expression of ZFP91 mRNA

NCBI chr 1:209,891,344...209,928,890
Ensembl chr 1:209,891,344...209,927,762

G

Zic family member 4

decreases expression

acetylhydrazine results in decreased expression of ZIC4 mRNA

NCBI chr 8:91,916,356...91,936,525
Ensembl chr 8:91,920,015...91,935,368

AM-251

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily G member 2

multiple interactions
increases expression

4'-methoxy-1-naphthylfenoterol inhibits the reaction [AM 251 results in increased expression of ABCG2 protein]; 4-(4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1H,4H,5H,6H-pyrrolo(3,4-c)pyrazol-5-yl)benzoic acid inhibits the reaction [AM 251 results in increased expression of ABCG2 protein]

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

actin alpha 2, smooth muscle

multiple interactions

AM 251 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

agouti related neuropeptide

multiple interactions
increases expression

AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AGRP mRNA]
AM 251 results in increased expression of AGRP mRNA

NCBI chr19:33,447,992...33,481,602
Ensembl chr19:33,447,992...33,449,584

G

AKT serine/threonine kinase 1

multiple interactions

AM 251 inhibits the reaction [Cannabidiol results in increased phosphorylation of AKT1 protein]; AM 251 inhibits the reaction [Dronabinol results in decreased phosphorylation of and results in decreased activity of AKT1 protein]
AM 251 inhibits the reaction [[3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide co-treated with Glutamic Acid] results in increased phosphorylation of AKT1 protein]; AM 251 inhibits the reaction [[cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester co-treated with Glutamic Acid] results in increased phosphorylation of AKT1 protein]; AM 251 inhibits the reaction [[JZL 184 co-treated with Glutamic Acid] results in increased phosphorylation of AKT1 protein]; AM 251 inhibits the reaction [Dietary Fats results in decreased expression of AKT1 protein]

PMID:17583570 PMID:26847930 PMID:27543109 PMID:33817834

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

actin related protein 2/3 complex, subunit 4

decreases expression

AM 251 results in decreased expression of ARPC4 mRNA

NCBI chr 4:146,522,255...146,532,784
Ensembl chr 4:146,522,176...146,532,785

G

cAMP regulated phosphoprotein 21

increases expression

AM 251 results in increased expression of ARPP21 mRNA

NCBI chr 8:112,034,636...112,199,273
Ensembl chr 8:112,034,642...112,194,297

G

argininosuccinate synthase 1

increases expression

AM 251 results in increased expression of ASS1 mRNA

NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903

G

activating transcription factor 5

increases expression

AM 251 results in increased expression of ATF5 mRNA

NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707

G

arginine vasopressin

multiple interactions
increases expression

AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA]
AM 251 results in increased expression of AVP mRNA

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

BCL2, apoptosis regulator

increases expression
multiple interactions

AM 251 results in increased expression of BCL2 protein
AM 251 inhibits the reaction [Streptozocin results in decreased expression of BCL2 protein]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bradykinin receptor B1

multiple interactions

AM 251 inhibits the reaction [anandamide results in decreased activity of BDKRB1 protein]

NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747

G

brain-derived neurotrophic factor

multiple interactions

AM 251 inhibits the reaction [Morphine results in increased expression of BDNF protein]

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

BTG anti-proliferation factor 2

multiple interactions

AM 251 inhibits the reaction [Ethanol results in increased expression of BTG2 mRNA]

NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628

G

cyclase associated actin cytoskeleton regulatory protein 2

decreases expression

AM 251 results in decreased expression of CAP2 mRNA

NCBI chr17:18,054,234...18,203,453
Ensembl chr17:18,054,431...18,203,373

G

cysteinyl-tRNA synthetase 1

increases expression

AM 251 results in increased expression of CARS1 mRNA

NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941

G

CART prepropeptide

increases expression
multiple interactions

AM 251 results in increased expression of CARTPT mRNA
[AM 251 co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA

NCBI chr 2:31,255,098...31,257,452
Ensembl chr 2:31,255,098...31,290,713

G

caspase 1

multiple interactions

AM 251 inhibits the reaction [Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 protein]]

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caveolae associated protein 2

decreases expression

AM 251 results in decreased expression of CAVIN2 mRNA

NCBI chr 9:50,302,079...50,314,096
Ensembl chr 9:50,301,206...50,314,147

G

coiled-coil domain containing 86

decreases expression

AM 251 results in decreased expression of CCDC86 mRNA

NCBI chr 1:207,590,167...207,596,547
Ensembl chr 1:207,590,168...207,596,544

G

cyclin D2

increases expression
multiple interactions

AM 251 results in increased expression of CCND2 protein
AM 251 inhibits the reaction [Streptozocin results in decreased expression of CCND2 protein]

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

CD55 molecule (Cromer blood group)

increases expression

AM 251 results in increased expression of CD55 mRNA

NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831

G

cadherin 1

increases expression
multiple interactions

AM 251 results in increased expression of CDH1 protein
AM 251 inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 mRNA]; AM 251 inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

CCAAT/enhancer binding protein gamma

increases expression

AM 251 results in increased expression of CEBPG mRNA

NCBI chr 1:87,683,060...87,692,772
Ensembl chr 1:87,684,019...87,694,569

G

cholinergic receptor nicotinic beta 3 subunit

increases expression

AM 251 results in increased expression of CHRNB3 mRNA

NCBI chr16:64,713,438...64,751,360
Ensembl chr16:64,714,169...64,751,360

G

chemokine-like factor

increases expression

AM 251 results in increased expression of CKLF mRNA

NCBI chr19:698,097...706,570
Ensembl chr19:698,033...706,570

G

cannabinoid receptor 1

multiple interactions
increases methylation
decreases activity

[AM 251 binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to 1-(5-fluoropentyl)-3-(1-naphthoyl)indole; [AM 251 binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to 1-pentyl-3-(1-naphthoyl)indole; [AM 251 binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; [AM 251 binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone; [AM 251 binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to CP 47497; [AM 251 binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to CP 47497 analog; [AM 251 binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to HU 211; AM 251 inhibits the reaction [Dietary Fats results in increased expression of CNR1 protein]; AM 251 inhibits the reaction [Ethanol results in increased expression of CNR1 mRNA]
AM 251 inhibits the reaction [Cannabidiol results in increased expression of CNR1 protein]
AM 251 results in increased methylation of CNR1 promoter
AM 251 results in decreased activity of CNR1 protein
[AM 251 binds to and results in decreased activity of CNR1 protein] which results in decreased activity of nimesulide; AM 251 binds to and results in decreased activity of CNR1 protein; AM 251 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of CNR1 mRNA]; AM 251 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of CNR1 protein]; AM 251 inhibits the reaction [1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester binds to and results in increased activity of CNR1 protein]; AM 251 inhibits the reaction [1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester binds to and results in increased activity of CNR1 protein]; AM 251 inhibits the reaction [Dietary Carbohydrates results in decreased expression of CNR1 protein]; AM 251 inhibits the reaction [HU 211 results in decreased expression of CNR1 protein]; AM 251 inhibits the reaction [Methylazoxymethanol Acetate results in increased expression of CNR1 mRNA]; AM 251 inhibits the reaction [N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide binds to and results in increased activity of CNR1 protein]; AM 251 inhibits the reaction [N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide binds to and results in increased activity of CNR1 protein]

PMID:12509806 PMID:17596442 PMID:20590570 PMID:21907772 PMID:24211273 More...

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

collagen type I alpha 1 chain

multiple interactions

AM 251 inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

multiple interactions

AM 251 inhibits the reaction [TGFB1 protein results in increased expression of COL1A2 mRNA]

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

collagen type IV alpha 1 chain

multiple interactions

AM 251 inhibits the reaction [TGFB1 protein results in increased expression of COL4A1 mRNA]

NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412

G

cytochrome c oxidase subunit 4i1

multiple interactions

AM 251 inhibits the reaction [Dietary Carbohydrates results in decreased expression of COX4I1 mRNA]; AM 251 inhibits the reaction [Dietary Fats results in decreased expression of COX4I1 mRNA]

NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921

G

carnitine palmitoyltransferase 1A

multiple interactions

AM 251 inhibits the reaction [Dietary Fats results in decreased expression of CPT1A mRNA]

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

cAMP responsive element binding protein 1

multiple interactions

AM 251 inhibits the reaction [Morphine results in increased phosphorylation of CREB1 protein]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

cAMP responsive element binding protein 3-like 3

multiple interactions
decreases expression

AM 251 inhibits the reaction [Ethanol results in increased cleavage of and results in increased activity of CREB3L3 protein]; AM 251 inhibits the reaction [Ethanol results in increased expression of CREB3L3 mRNA]
AM 251 results in decreased expression of CREB3L3 mRNA

NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048

G

corticotropin releasing hormone

multiple interactions
increases expression

[AM 251 co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CRH mRNA
AM 251 results in increased expression of CRH mRNA

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

citrate synthase

multiple interactions

AM 251 inhibits the reaction [Dietary Fats results in decreased expression of CS mRNA]

NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421

G

cystathionine gamma-lyase

increases expression

AM 251 results in increased expression of CTH mRNA

NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234

G

C-X-C motif chemokine ligand 3

multiple interactions

AM 251 inhibits the reaction [Ceruletide results in increased expression of CXCL1 mRNA]; AM 251 promotes the reaction [iodopravadoline inhibits the reaction [Ceruletide results in increased expression of CXCL1 mRNA]]; iodopravadoline promotes the reaction [AM 251 inhibits the reaction [Ceruletide results in increased expression of CXCL1 mRNA]]

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

cytochrome P450, family 27, subfamily a, polypeptide 1

multiple interactions

AM 251 inhibits the reaction [Ethanol results in increased expression of CYP27A1 mRNA]

PMID:23894352 PMID:28095641

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

AM 251 inhibits the reaction [Ethanol results in increased expression of CYP7A1 mRNA]

PMID:23894352 PMID:28095641

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 7 subfamily B member 1

decreases expression
multiple interactions

AM 251 results in decreased expression of CYP7B1 mRNA
AM 251 inhibits the reaction [Ethanol results in increased expression of CYP7B1 mRNA]

NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698

G

cytochrome P450 family 8 subfamily B member 1

multiple interactions

AM 251 inhibits the reaction [Ethanol results in increased expression of CYP8B1 mRNA]

PMID:23894352 PMID:28095641

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

DNA-damage inducible transcript 3

increases expression

AM 251 results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

DNA-damage-inducible transcript 4

increases expression

AM 251 results in increased expression of DDIT4 mRNA

NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105

G

DExH-box helicase 9

decreases expression

AM 251 results in decreased expression of DHX9 mRNA

NCBI chr13:65,602,322...65,639,098
Ensembl chr13:65,602,323...65,639,069

G

dihydrolipoamide dehydrogenase

multiple interactions
decreases expression
increases activity

AM 251 inhibits the reaction [Dietary Carbohydrates results in decreased expression of DLD mRNA]; AM 251 inhibits the reaction [Dietary Carbohydrates results in decreased expression of DLD protein]
AM 251 promotes the reaction [INS1 protein results in increased activity of DLD protein]
AM 251 results in decreased expression of DLD mRNA
AM 251 results in increased activity of DLD protein

NCBI chr 6:47,904,153...47,924,814
Ensembl chr 6:47,903,914...47,924,795

G

elongation factor Tu GTP binding domain containing 2

decreases expression

AM 251 results in decreased expression of EFTUD2 mRNA

NCBI chr10:87,804,893...87,852,181
Ensembl chr10:87,804,892...87,846,079

G

epidermal growth factor receptor

multiple interactions
increases expression

4'-methoxy-1-naphthylfenoterol inhibits the reaction [AM 251 results in increased expression of EGFR protein]; 4-(4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1H,4H,5H,6H-pyrrolo(3,4-c)pyrazol-5-yl)benzoic acid inhibits the reaction [AM 251 results in increased expression of EGFR protein]

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

enolase 3

multiple interactions

AM 251 inhibits the reaction [Dietary Carbohydrates results in increased expression of ENO3 protein]

NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921

G

endogenous retrovirus group FRD member 1, envelope

multiple interactions

AM 251 affects the reaction [Dronabinol results in decreased expression of ERVFRD-1 mRNA]

NCBI chr12:22,151,211...22,158,264
Ensembl chr12:22,151,211...22,158,264

G

coagulation factor III, tissue factor

multiple interactions

[AM 251 co-treated with iodopravadoline] promotes the reaction [IL1B protein results in increased expression of and results in increased activity of F3 protein]; [AM 251 co-treated with iodopravadoline] promotes the reaction [methanandamide promotes the reaction [IL1B protein results in increased expression of and results in increased activity of F3 protein]]

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

flap structure-specific endonuclease 1

decreases expression

AM 251 results in decreased expression of FEN1 mRNA

NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

AM 251 inhibits the reaction [Dietary Fats results in increased expression of FOS protein]; AM 251 inhibits the reaction [LEP gene mutant form results in increased expression of FOS protein]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FosB proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

AM 251 inhibits the reaction [TGFB1 protein results in increased expression of FOSB mRNA]
AM 251 results in increased expression of FOSB mRNA

NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465

G

forkhead box O1

multiple interactions

AM 251 inhibits the reaction [Dietary Fats results in decreased phosphorylation of FOXO1 protein]

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

FRA10A associated CGG repeat 1

increases expression

AM 251 results in increased expression of FRA10AC1 mRNA

NCBI chr 1:235,969,071...236,001,074
Ensembl chr 1:235,969,112...236,001,210

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

AM 251 inhibits the reaction [Dietary Fats results in increased expression of G6PC1 protein]

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

glyoxalase 1

decreases expression
multiple interactions

AM 251 results in decreased expression of GLO1 protein
AM 251 inhibits the reaction [Dietary Carbohydrates results in decreased expression of GLO1 protein]; AM 251 inhibits the reaction [Dietary Fats results in decreased expression of GLO1 protein]

NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649

G

glucose-6-phosphate isomerase

multiple interactions
decreases expression

AM 251 inhibits the reaction [Dietary Carbohydrates results in increased expression of GPI protein]
AM 251 results in decreased expression of GPI protein

NCBI chr 1:86,828,211...86,856,077
Ensembl chr 1:86,828,216...86,856,086

G

G protein-coupled receptor 55

multiple interactions
increases activity

4'-methoxy-1-naphthylfenoterol inhibits the reaction [AM 251 results in increased activity of GPR55 protein]; 4-(4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1H,4H,5H,6H-pyrrolo(3,4-c)pyrazol-5-yl)benzoic acid inhibits the reaction [AM 251 results in increased activity of GPR55 protein]

NCBI chr 9:86,584,906...86,640,601
Ensembl chr 9:86,590,885...86,640,613

G

glutathione peroxidase 1

increases expression

AM 251 results in increased expression of GPX1 mRNA

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione-disulfide reductase

multiple interactions

AM 251 promotes the reaction [INS1 protein results in increased activity of GSR protein]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

general transcription factor IIIC subunit 5

decreases expression

AM 251 results in decreased expression of GTF3C5 mRNA

NCBI chr 3:11,893,867...11,914,187
Ensembl chr 3:11,893,875...11,914,180

G

HCLS1 associated protein X-1

increases expression

AM 251 results in increased expression of HAX1 mRNA

NCBI chr 2:175,434,242...175,437,926
Ensembl chr 2:175,434,238...175,437,714

G

hypocretin neuropeptide precursor

multiple interactions

AM 251 inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of HCRT mRNA]
AM 251 inhibits the reaction [Dietary Fats results in increased expression of HCRT protein modified form]; AM 251 inhibits the reaction [HCRT protein modified form results in increased expression of POMC mRNA]; AM 251 inhibits the reaction [HCRT protein modified form results in increased expression of POMC protein modified form]; AM 251 inhibits the reaction [HCRT protein modified form results in increased expression of POMC protein]; AM 251 inhibits the reaction [HCRT protein modified form results in increased phosphorylation of and results in increased activity of STAT3 protein]; AM 251 inhibits the reaction [HCRT protein modified form results in increased phosphorylation of MAPK1 protein]; AM 251 inhibits the reaction [HCRT protein modified form results in increased phosphorylation of MAPK3 protein]; AM 251 inhibits the reaction [LEP gene mutant form results in increased expression of HCRT protein modified form]

PMID:26468265 PMID:27071101

NCBI chr10:85,689,979...85,691,214
Ensembl chr10:85,689,465...85,691,210

G

histone cluster 1 H2A family like 1

increases expression

AM 251 results in increased expression of H2AC6 mRNA

NCBI chr17:42,707,954...42,708,420

G

heme oxygenase 1

increases expression

AM 251 results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

histamine N-methyltransferase

increases expression

AM 251 results in increased expression of HNMT mRNA

NCBI chr 3:6,591,804...6,623,821
Ensembl chr 3:6,591,463...6,624,012

G

heat shock protein family A (Hsp70) member 1B

decreases expression

AM 251 results in decreased expression of HSPA1B mRNA

NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
Ensembl chr20:3,856,006...3,873,240

G

heat shock protein family A (Hsp70) member 8

decreases expression

AM 251 results in decreased expression of HSPA8 mRNA

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

intercellular adhesion molecule 1

multiple interactions

AM 251 inhibits the reaction [Cannabidiol results in increased expression of ICAM1 mRNA]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interleukin 1 beta

multiple interactions

[AM 251 co-treated with iodopravadoline] promotes the reaction [IL1B protein results in increased expression of and results in increased activity of F3 protein]; [AM 251 co-treated with iodopravadoline] promotes the reaction [methanandamide promotes the reaction [IL1B protein results in increased expression of and results in increased activity of F3 protein]]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 33

multiple interactions

AM 251 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [Carbon Monoxide results in increased expression of IL33 protein]]

NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373

G

inner mitochondrial membrane peptidase subunit 2

increases expression

AM 251 results in increased expression of IMMP2L mRNA

NCBI chr 6:58,070,035...58,970,165
Ensembl chr 6:58,070,283...58,969,840

G

insulin 1

multiple interactions

AM 251 inhibits the reaction [Streptozocin results in decreased expression of INS1 protein]; AM 251 promotes the reaction [INS1 protein results in increased activity of DLD protein]; AM 251 promotes the reaction [INS1 protein results in increased activity of GSR protein]

PMID:26671069 PMID:26967640

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

interferon regulatory factor 2 binding protein-like

increases expression

AM 251 results in increased expression of IRF2BPL mRNA

NCBI chr 6:106,527,179...106,531,294
Ensembl chr 6:106,528,053...106,530,401

G

insulin receptor substrate 2

multiple interactions

AM 251 inhibits the reaction [Dietary Fats results in decreased phosphorylation of IRS2 protein]

NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

AM 251 inhibits the reaction [TGFB1 protein results in increased expression of JUNB mRNA]

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

lactate dehydrogenase A

multiple interactions

AM 251 inhibits the reaction [Dietary Carbohydrates results in increased expression of LDHA protein]

NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472

G

leptin

multiple interactions

AM 251 inhibits the reaction [LEP gene mutant form results in decreased expression of POMC mRNA]; AM 251 inhibits the reaction [LEP gene mutant form results in decreased expression of POMC protein]; AM 251 inhibits the reaction [LEP gene mutant form results in decreased secretion of POMC protein modified form]; AM 251 inhibits the reaction [LEP gene mutant form results in increased expression of FOS protein]; AM 251 inhibits the reaction [LEP gene mutant form results in increased expression of HCRT protein modified form]

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

lamin B2

decreases expression

AM 251 results in decreased expression of LMNB2 mRNA

NCBI chr 7:8,792,628...8,808,665
Ensembl chr 7:8,789,314...8,808,665

G

mitogen activated protein kinase kinase 3

decreases expression

AM 251 results in decreased expression of MAP2K3 mRNA

NCBI chr10:45,608,145...45,629,492
Ensembl chr10:45,607,163...45,629,492

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; AM 251 inhibits the reaction [Dronabinol results in decreased phosphorylation of and results in decreased activity of MAPK1 protein]; AM 251 inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK1 protein]; AM 251 inhibits the reaction [methanandamide results in increased phosphorylation of MAPK1 protein]
AM 251 inhibits the reaction [[3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide co-treated with Glutamic Acid] results in increased phosphorylation of MAPK1 protein]; AM 251 inhibits the reaction [[cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester co-treated with Glutamic Acid] results in increased phosphorylation of MAPK1 protein]; AM 251 inhibits the reaction [[JZL 184 co-treated with Glutamic Acid] results in increased phosphorylation of MAPK1 protein]; AM 251 inhibits the reaction [HCRT protein modified form results in increased phosphorylation of MAPK1 protein]; AM 251 inhibits the reaction [Morphine results in increased phosphorylation of MAPK1 protein]
AM 251 results in increased phosphorylation of MAPK1 protein

PMID:17583570 PMID:17596442 PMID:18159069 PMID:19477951 PMID:27071101 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; AM 251 inhibits the reaction [Dronabinol results in decreased phosphorylation of and results in decreased activity of MAPK3 protein]; AM 251 inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK3 protein]; AM 251 inhibits the reaction [methanandamide results in increased phosphorylation of MAPK3 protein]
AM 251 inhibits the reaction [[3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide co-treated with Glutamic Acid] results in increased phosphorylation of MAPK3 protein]; AM 251 inhibits the reaction [[cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester co-treated with Glutamic Acid] results in increased phosphorylation of MAPK3 protein]; AM 251 inhibits the reaction [[JZL 184 co-treated with Glutamic Acid] results in increased phosphorylation of MAPK3 protein]; AM 251 inhibits the reaction [HCRT protein modified form results in increased phosphorylation of MAPK3 protein]; AM 251 inhibits the reaction [Morphine results in increased phosphorylation of MAPK3 protein]
AM 251 results in increased phosphorylation of MAPK3 protein

PMID:17583570 PMID:17596442 PMID:18159069 PMID:19477951 PMID:27071101 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

minichromosome maintenance complex component 3

decreases expression

AM 251 results in decreased expression of MCM3 mRNA

NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314

G

minichromosome maintenance complex component 5

decreases expression

AM 251 results in decreased expression of MCM5 mRNA

NCBI chr19:13,483,030...13,504,389
Ensembl chr19:13,483,066...13,504,389

G

mitofusin 2

decreases expression

AM 251 results in decreased expression of MFN2 mRNA

NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342

G

matrix metallopeptidase 2

multiple interactions
increases expression

AM 251 inhibits the reaction [TGFB1 protein results in increased expression of MMP2 mRNA]
AM 251 results in increased expression of MMP2 protein

PMID:27936102 PMID:29883990

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

non-SMC condensin II complex, subunit D3

decreases expression

AM 251 results in decreased expression of NCAPD3 mRNA

NCBI chr 8:25,437,067...25,506,375
Ensembl chr 8:25,437,123...25,506,373

G

nuclear receptor coactivator 7

increases expression

AM 251 results in increased expression of NCOA7 mRNA

NCBI chr 1:26,856,228...27,016,950
Ensembl chr 1:26,856,530...27,015,871

G

neuropeptide Y

multiple interactions

[AM 251 co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of NPY mRNA

NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495

G

nuclear respiratory factor 1

multiple interactions

AM 251 inhibits the reaction [Dietary Fats results in decreased expression of NRF1 mRNA]

NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328

G

opioid related nociceptin receptor 1

multiple interactions

AM 251 inhibits the reaction [Dronabinol results in decreased expression of OPRL1 mRNA]; AM 251 inhibits the reaction [Dronabinol results in decreased expression of OPRL1 protein]

NCBI chr 3:168,831,934...168,839,920
Ensembl chr 3:168,834,003...168,839,920

G

oxytocin/neurophysin I prepropeptide

multiple interactions
increases secretion
increases expression

AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]
AM 251 results in increased secretion of OXT protein
AM 251 results in increased expression of OXT mRNA

NCBI chr 3:117,782,650...117,783,490
Ensembl chr 3:117,782,650...117,783,490

G

poly (A) polymerase alpha

decreases expression

AM 251 results in decreased expression of PAPOLA mRNA

NCBI chr 6:124,682,015...124,734,706
Ensembl chr 6:124,682,105...124,734,468

G

poly (ADP-ribose) polymerase 1

multiple interactions

AM 251 inhibits the reaction [HU 211 results in increased cleavage of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

phosphoenolpyruvate carboxykinase 1

multiple interactions

AM 251 inhibits the reaction [Dietary Fats results in increased expression of PCK1 mRNA]; AM 251 inhibits the reaction [Dietary Fats results in increased expression of PCK1 protein]

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

proliferation and apoptosis adaptor protein 15

increases expression

AM 251 results in increased expression of PEA15 mRNA

NCBI chr13:84,657,815...84,667,437
Ensembl chr13:84,654,870...84,667,499

G

proopiomelanocortin

multiple interactions
increases expression

AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA]
AM 251 inhibits the reaction [Dietary Fats results in decreased expression of POMC mRNA]; AM 251 inhibits the reaction [Dietary Fats results in decreased expression of POMC protein]; AM 251 inhibits the reaction [Dietary Fats results in decreased secretion of POMC protein modified form]; AM 251 inhibits the reaction [HCRT protein modified form results in increased expression of POMC mRNA]; AM 251 inhibits the reaction [HCRT protein modified form results in increased expression of POMC protein modified form]; AM 251 inhibits the reaction [HCRT protein modified form results in increased expression of POMC protein]; AM 251 inhibits the reaction [LEP gene mutant form results in decreased expression of POMC mRNA]; AM 251 inhibits the reaction [LEP gene mutant form results in decreased expression of POMC protein]; AM 251 inhibits the reaction [LEP gene mutant form results in decreased secretion of POMC protein modified form]
AM 251 results in increased expression of POMC mRNA

PMID:26468265 PMID:27071101

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

peptidylprolyl isomerase F

decreases expression

AM 251 results in decreased expression of PPIF mRNA

NCBI chr16:1,257,197...1,263,919
Ensembl chr16:1,257,106...1,263,913

G

polypyrimidine tract binding protein 1

decreases expression

AM 251 results in decreased expression of PTBP1 mRNA

NCBI chr 7:9,842,574...9,852,332
Ensembl chr 7:9,842,574...9,852,397

G

protein tyrosine kinase 2

multiple interactions

[AM 251 co-treated with iodopravadoline] inhibits the reaction [Dronabinol results in increased phosphorylation of PTK2 protein]

NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783

G

Rac GTPase-activating protein 1

decreases expression

AM 251 results in decreased expression of RACGAP1 mRNA

NCBI chr 7:130,750,936...130,780,891
Ensembl chr 7:130,750,936...130,780,831

G

RAD54 like

decreases expression

AM 251 results in decreased expression of RAD54L mRNA

NCBI chr 5:129,575,431...129,605,100
Ensembl chr 5:129,575,378...129,605,070

G

regulator of chromosome condensation 1

decreases expression

AM 251 results in decreased expression of RCC1 mRNA

NCBI chr 5:144,526,025...144,544,445
Ensembl chr 5:144,526,025...144,544,577

G

RCC1 like

decreases expression

AM 251 results in decreased expression of RCC1L mRNA

NCBI chr12:22,543,125...22,574,042
Ensembl chr12:22,543,734...22,574,036

G

replication factor C subunit 5

decreases expression

AM 251 results in decreased expression of RFC5 mRNA

NCBI chr12:39,207,484...39,217,041
Ensembl chr12:39,207,484...39,217,312

G

ribonuclease H1

increases expression

AM 251 results in increased expression of RNASEH1 mRNA

NCBI chr 6:45,282,849...45,292,258
Ensembl chr 6:45,282,854...45,292,236

G

replication protein A1

decreases expression

AM 251 results in decreased expression of RPA1 mRNA

NCBI chr10:60,148,869...60,199,970
Ensembl chr10:60,148,793...60,199,949

G

RWD domain containing 1

increases expression

AM 251 results in increased expression of RWDD1 mRNA

NCBI chr20:25,949,723...25,967,147
Ensembl chr20:25,941,966...25,967,193

G

S100 calcium binding protein A2

increases expression

AM 251 results in increased expression of S100A2 mRNA

NCBI chr 2:176,077,081...176,078,325

G

seryl-tRNA synthetase 1

increases expression

AM 251 results in increased expression of SARS1 mRNA

NCBI chr 2:196,065,543...196,081,240
Ensembl chr 2:196,065,430...196,081,277

G

sestrin 2

increases expression

AM 251 results in increased expression of SESN2 mRNA

NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260

G

solute carrier family 18 member B1

decreases expression

AM 251 results in decreased expression of SLC18B1 mRNA

NCBI chr 1:21,628,235...21,670,807
Ensembl chr 1:21,628,237...21,670,684

G

solute carrier family 1 member 4

increases expression

AM 251 results in increased expression of SLC1A4 mRNA

NCBI chr14:94,530,801...94,560,190
Ensembl chr14:94,529,084...94,560,418

G

solute carrier family 30 member 1

increases expression

AM 251 results in increased expression of SLC30A1 mRNA

NCBI chr13:103,491,037...103,494,910
Ensembl chr13:103,491,037...103,494,910

G

solute carrier family 46 member 1

increases expression

AM 251 results in increased expression of SLC46A1 mRNA

NCBI chr10:63,361,504...63,367,940
Ensembl chr10:63,361,486...63,368,848

G

solute carrier family 6 member 3

multiple interactions

AM 251 affects the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the expression of SLC6A3 mRNA]

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

G

solute carrier family 7 member 5

increases expression

AM 251 results in increased expression of SLC7A5 mRNA

NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823

G

SMAD family member 3

multiple interactions

AM 251 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]

NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960

G

snail family transcriptional repressor 1

decreases expression
multiple interactions

AM 251 results in decreased expression of SNAI1 mRNA
AM 251 inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]

NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969

G

snail family transcriptional repressor 2

multiple interactions

AM 251 inhibits the reaction [TGFB1 protein results in increased expression of SNAI2 mRNA]

NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200

G

spectrin, beta, non-erythrocytic 1

decreases expression

AM 251 results in decreased expression of SPTBN1 mRNA

NCBI chr14:103,841,713...104,016,900
Ensembl chr14:103,842,684...104,008,507

G

serine and arginine rich splicing factor 1

decreases expression

AM 251 results in decreased expression of SRSF1 mRNA

NCBI chr10:72,838,926...72,859,066
Ensembl chr10:72,839,274...72,845,336

G

signal transducing adaptor molecule

decreases expression

AM 251 results in decreased expression of STAM mRNA

NCBI chr17:77,120,235...77,166,173
Ensembl chr17:77,120,158...77,166,467

G

signal transducer and activator of transcription 3

decreases expression
multiple interactions

AM 251 results in decreased expression of STAT3 mRNA
AM 251 inhibits the reaction [Cannabidiol results in increased phosphorylation of STAT3 protein]
AM 251 inhibits the reaction [HCRT protein modified form results in increased phosphorylation of and results in increased activity of STAT3 protein]

PMID:16500647 PMID:27071101 PMID:33817834

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

SURP and G patch domain containing 2

decreases expression

AM 251 results in decreased expression of SUGP2 mRNA

NCBI chr16:19,159,951...19,191,412
Ensembl chr16:19,164,767...19,191,340

G

Sad1 and UNC84 domain containing 1

decreases expression

AM 251 results in decreased expression of SUN1 mRNA

NCBI chr12:15,396,378...15,441,277
Ensembl chr12:15,396,381...15,441,571

G

transforming, acidic coiled-coil containing protein 3

decreases expression

AM 251 results in decreased expression of TACC3 mRNA

NCBI chr14:77,051,209...77,065,343
Ensembl chr14:77,051,215...77,065,219

G

transducin (beta)-like 1 X-linked

increases expression

AM 251 results in increased expression of TBL1X mRNA

NCBI chr X:41,574,558...41,731,117
Ensembl chr X:41,576,047...41,731,101

G

transcription factor A, mitochondrial

multiple interactions

AM 251 inhibits the reaction [Dietary Fats results in decreased expression of TFAM mRNA]

NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292

G

transforming growth factor, beta 1

multiple interactions

AM 251 inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 mRNA]; AM 251 inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; AM 251 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; AM 251 inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; AM 251 inhibits the reaction [TGFB1 protein results in increased expression of COL1A2 mRNA]; AM 251 inhibits the reaction [TGFB1 protein results in increased expression of COL4A1 mRNA]; AM 251 inhibits the reaction [TGFB1 protein results in increased expression of FOSB mRNA]; AM 251 inhibits the reaction [TGFB1 protein results in increased expression of JUNB mRNA]; AM 251 inhibits the reaction [TGFB1 protein results in increased expression of MMP2 mRNA]; AM 251 inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; AM 251 inhibits the reaction [TGFB1 protein results in increased expression of SNAI2 mRNA]; AM 251 inhibits the reaction [TGFB1 protein results in increased expression of TGFB2 mRNA]; AM 251 inhibits the reaction [TGFB1 protein results in increased expression of TGFB3 mRNA]; AM 251 inhibits the reaction [TGFB1 protein results in increased expression of TGFBR1 mRNA]; AM 251 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transforming growth factor, beta 2

multiple interactions

AM 251 inhibits the reaction [TGFB1 protein results in increased expression of TGFB2 mRNA]

NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405

G

transforming growth factor, beta 3

multiple interactions

AM 251 inhibits the reaction [TGFB1 protein results in increased expression of TGFB3 mRNA]

NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564

G

transforming growth factor, beta receptor 1

multiple interactions

AM 251 inhibits the reaction [TGFB1 protein results in increased expression of TGFBR1 mRNA]

NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777

G

tyrosine hydroxylase

multiple interactions

AM 251 affects the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the expression of TH mRNA]

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

TIMP metallopeptidase inhibitor 1

multiple interactions

[iodopravadoline co-treated with AM 251] inhibits the reaction [Dronabinol results in increased expression of TIMP1 protein]; [iodopravadoline co-treated with AM 251] inhibits the reaction [methanandamide results in increased expression of TIMP1 protein]; AM 251 inhibits the reaction [Dronabinol results in increased expression of TIMP1 protein]; AM 251 inhibits the reaction [methanandamide results in increased expression of TIMP1 protein]

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

transmembrane protein 126A

increases expression

AM 251 results in increased expression of TMEM126A mRNA

NCBI chr 1:144,424,481...144,430,730
Ensembl chr 1:144,422,703...144,430,628

G

tumor necrosis factor

decreases response to substance

AM 251 results in decreased susceptibility to TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tribbles pseudokinase 3

increases expression

AM 251 results in increased expression of TRIB3 mRNA

NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497

G

tetraspanin 10

increases expression

AM 251 results in increased expression of TSPAN10 mRNA

NCBI chr10:105,715,803...105,721,503
Ensembl chr10:105,715,961...105,719,813

G

thioredoxin interacting protein

increases expression

AM 251 results in increased expression of TXNIP mRNA

NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886

G

UDP-glucose ceramide glucosyltransferase

decreases expression

AM 251 results in decreased expression of UGCG mRNA

NCBI chr 5:74,032,978...74,065,701
Ensembl chr 5:74,032,978...74,065,393

G

ubiquitin-like with PHD and ring finger domains 1

decreases expression

AM 251 results in decreased expression of UHRF1 mRNA

NCBI chr 9:1,133,117...1,154,639
Ensembl chr 9:1,134,909...1,154,631

G

vascular endothelial growth factor A

multiple interactions

AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein]]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vascular endothelial growth factor C

multiple interactions

AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFC protein]]

NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848

G

very low density lipoprotein receptor

increases expression

AM 251 results in increased expression of VLDLR mRNA

NCBI chr 1:224,813,539...224,850,400
Ensembl chr 1:224,814,377...224,845,920

G

tryptophanyl-tRNA synthetase 1

increases expression

AM 251 results in increased expression of WARS1 mRNA

NCBI chr 6:127,776,088...127,807,273
Ensembl chr 6:127,776,090...127,807,269

G

X-box binding protein 1

increases expression

AM 251 results in increased expression of XBP1 mRNA

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

G

tyrosyl-tRNA synthetase 1

increases expression

AM 251 results in increased expression of YARS1 mRNA

NCBI chr 5:141,535,815...141,564,029
Ensembl chr 5:141,535,759...141,563,833

G

YY1 transcription factor

multiple interactions

AM 251 inhibits the reaction [Ethanol results in increased expression of YY1 mRNA]

NCBI chr 6:127,706,739...127,736,499
Ensembl chr 6:127,707,596...127,732,747

G

zinc finger protein 142

decreases expression

AM 251 results in decreased expression of ZNF142 mRNA

NCBI chr 9:76,141,053...76,164,784
Ensembl chr 9:76,142,227...76,164,856

G

zinc finger MYM-type containing 6

increases expression

AM 251 results in increased expression of ZMYM6 mRNA

NCBI chr 5:139,396,374...139,444,357
Ensembl chr 5:139,396,727...139,444,279

AM6545

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin II receptor, type 1a

multiple interactions

[Perindopril co-treated with AM6545] inhibits the reaction [Streptozocin results in increased expression of AGTR1A protein]; AM6545 inhibits the reaction [Streptozocin results in increased expression of AGTR1A mRNA]; AM6545 inhibits the reaction [Streptozocin results in increased expression of AGTR1A protein]

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

albumin

multiple interactions

AM6545 inhibits the reaction [Streptozocin results in increased expression of ALB protein]

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

arginase 1

multiple interactions

AM6545 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the expression of ARG1 mRNA]; AM6545 inhibits the reaction [Streptozocin results in decreased expression of ARG1 mRNA]; Perindopril inhibits the reaction [AM6545 inhibits the reaction [Streptozocin results in decreased expression of ARG1 mRNA]]

NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422

G

C-C motif chemokine ligand 2

multiple interactions

[AM6545 co-treated with Perindopril] inhibits the reaction [Streptozocin results in increased expression of CCL2 mRNA]; [AM6545 co-treated with Perindopril] inhibits the reaction [Streptozocin results in increased expression of CCL2 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 3

multiple interactions

AM6545 inhibits the reaction [Streptozocin results in increased expression of CCL3 mRNA]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in increased expression of CCL3 mRNA]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in increased expression of CCL3 mRNA]]

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine receptor 2

multiple interactions

[AM6545 co-treated with Perindopril] inhibits the reaction [Streptozocin results in increased expression of CCR2 mRNA]; AM6545 inhibits the reaction [Streptozocin results in increased expression of CCR2 mRNA]

NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100

G

CD163 molecule

multiple interactions

AM6545 inhibits the reaction [Streptozocin results in decreased expression of CD163 mRNA]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in decreased expression of CD163 mRNA]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in decreased expression of CD163 mRNA]]

NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878

G

Cd68 molecule

multiple interactions

AM6545 inhibits the reaction [Streptozocin results in increased expression of CD68 mRNA]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in increased expression of CD68 mRNA]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in increased expression of CD68 mRNA]]

NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697

G

fibronectin 1

multiple interactions

[AM6545 co-treated with Perindopril] inhibits the reaction [Streptozocin results in increased expression of FN1 mRNA]; AM6545 inhibits the reaction [Streptozocin results in increased expression of FN1 mRNA]; AM6545 inhibits the reaction [Streptozocin results in increased expression of FN1 protein]

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

intercellular adhesion molecule 1

multiple interactions

AM6545 inhibits the reaction [Streptozocin results in increased expression of ICAM1 mRNA]; AM6545 inhibits the reaction [Streptozocin results in increased expression of ICAM1 protein]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in increased expression of ICAM1 mRNA]]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in increased expression of ICAM1 protein]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in increased expression of ICAM1 mRNA]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in increased expression of ICAM1 protein]]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

mannose receptor, C type 1

multiple interactions

AM6545 inhibits the reaction [Streptozocin results in decreased expression of MRC1 mRNA]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in decreased expression of MRC1 mRNA]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in decreased expression of MRC1 mRNA]]

NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857

G

nitric oxide synthase 2

multiple interactions

AM6545 inhibits the reaction [Streptozocin results in increased expression of NOS2 mRNA]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in increased expression of NOS2 mRNA]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in increased expression of NOS2 mRNA]]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NPHS2 stomatin family member, podocin

multiple interactions

AM6545 inhibits the reaction [Streptozocin results in decreased expression of NPHS2 mRNA]; AM6545 inhibits the reaction [Streptozocin results in decreased expression of NPHS2 protein]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in decreased expression of NPHS2 mRNA]]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in decreased expression of NPHS2 protein]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in decreased expression of NPHS2 mRNA]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in decreased expression of NPHS2 protein]]

NCBI chr13:68,448,720...68,461,312
Ensembl chr13:68,448,926...68,461,313

G

tumor necrosis factor

multiple interactions

AM6545 inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]; AM6545 inhibits the reaction [Streptozocin results in increased expression of TNF protein]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]]; AM6545 promotes the reaction [Perindopril inhibits the reaction [Streptozocin results in increased expression of TNF protein]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]]; Perindopril promotes the reaction [AM6545 inhibits the reaction [Streptozocin results in increased expression of TNF protein]]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

atazanavir sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity
multiple interactions

Atazanavir Sulfate results in decreased activity of ABCB11 protein
Atazanavir Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

increases transport
multiple interactions

ABCB1 protein results in increased transport of Atazanavir Sulfate
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB1 mRNA

PMID:29859254 PMID:33819548

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB4 mRNA

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 2

decreases expression

Atazanavir Sulfate results in decreased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

decreases expression

Atazanavir Sulfate results in decreased expression of ABCC3 mRNA

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily G member 2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ABCG2 mRNA

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

ATP binding cassette subfamily G member 5

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG5 mRNA

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

ATP binding cassette subfamily G member 8

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG8 mRNA

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

acyl-CoA synthetase long-chain family member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ACSL1 mRNA

NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541

G

adhesion G protein-coupled receptor G1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ADGRG1 mRNA

NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH1C mRNA

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892

G

alcohol dehydrogenase 4 (class II), pi polypeptide

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH4 mRNA

NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591

G

alcohol dehydrogenase 6 (class V)

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH6 mRNA

NCBI chr 2:226,903,208...226,934,564
Ensembl chr 2:226,903,250...226,934,534

G

aldo-keto reductase family 1, member D1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of AKR1D1 mRNA

NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372

G

aldo-keto reductase family 7 member A3

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of AKR7A3 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA

NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394

G

albumin

affects binding
multiple interactions

Atazanavir Sulfate binds to ALB protein
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALB mRNA

PMID:15814459 PMID:16336266 PMID:33819548

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

alkaline phosphatase, placental

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALPP mRNA

NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606

G

adenosine monophosphate deaminase 3

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of AMPD3 mRNA

NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887

G

apolipoprotein A1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of APOA1 mRNA

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

activating transcription factor 4

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA
Atazanavir Sulfate results in increased expression of ATF4 mRNA

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

activating transcription factor 6

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA
Atazanavir Sulfate results in increased expression of ATF6 mRNA

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

autophagy related 7

increases expression
multiple interactions

Atazanavir Sulfate results in increased expression of ATG7 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

ATPase phospholipid transporting 8B1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ATP8B1 mRNA

NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396

G

bile acid CoA:amino acid N-acyltransferase

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of BAAT mRNA

NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685

G

Bcl2-like 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of BCL2L1 mRNA

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

catalase

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of CAT mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

increases expression

Atazanavir Sulfate results in increased expression of CCL2 protein

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 3

increases expression

Atazanavir Sulfate results in increased expression of CCL3 protein

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

chitinase 3 like 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CHI3L1 mRNA

NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787

G

colony stimulating factor 1

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA
Atazanavir Sulfate results in increased expression of CSF1 mRNA

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

catenin beta 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CTNNB1 mRNA

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cortactin

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of CTTN mRNA

NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164

G

CYLD lysine 63 deubiquitinase

increases expression
multiple interactions

Atazanavir Sulfate results in increased expression of CYLD mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA

NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP1A2 mRNA

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 27, subfamily a, polypeptide 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP27A1 mRNA

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450, family 2, subfamily b, polypeptide 3

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of CYP2B6 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, subfamily 2, polypeptide 11

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C18 mRNA

NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C19 mRNA

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of CYP3A4 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP3A5 mRNA

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450 family 7 subfamily A member 1

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of CYP7A1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 7 subfamily B member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP7B1 mRNA

NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698

G

cytochrome P450 family 8 subfamily B member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP8B1 mRNA

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA
Atazanavir Sulfate results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

DnaJ heat shock protein family (Hsp40) member B9

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJB9 mRNA

NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063

G

DnaJ heat shock protein family (Hsp40) member C10

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA
Atazanavir Sulfate results in increased expression of DNAJC10 mRNA

NCBI chr 3:65,232,031...65,272,732
Ensembl chr 3:65,232,697...65,272,719

G

DnaJ heat shock protein family (Hsp40) member C12

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJC12 mRNA

NCBI chr20:25,246,744...25,267,508
Ensembl chr20:25,223,144...25,267,521

G

DnaJ heat shock protein family (Hsp40) member C9

increases expression

Atazanavir Sulfate results in increased expression of DNAJC9 mRNA

NCBI chr15:3,923,842...3,928,118
Ensembl chr15:3,923,268...3,928,118

G

epoxide hydrolase 1

multiple interactions
decreases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA
Atazanavir Sulfate results in decreased expression of EPHX1 mRNA

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

FKBP prolyl isomerase 5

multiple interactions
decreases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA
Atazanavir Sulfate results in decreased expression of FKBP5 mRNA

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

flavin containing dimethylaniline monoxygenase 1

decreases expression

Atazanavir Sulfate results in decreased expression of FMO1 mRNA

NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647

G

FOS like 1, AP-1 transcription factor subunit

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA
Atazanavir Sulfate results in increased expression of FOSL1 mRNA

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

gamma-glutamyltransferase 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GGT1 mRNA

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

gap junction protein, beta 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GJB1 mRNA

NCBI chr X:66,501,848...66,509,783
Ensembl chr X:66,501,820...66,509,925

G

glycerol kinase

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GK mRNA

NCBI chr X:50,162,089...50,238,707
Ensembl chr X:50,163,123...50,238,631

G

G protein-coupled receptor, class C, group 5, member B

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GPRC5B mRNA

NCBI chr 1:173,316,904...173,340,933
Ensembl chr 1:173,316,907...173,340,932

G

glutathione peroxidase 2

multiple interactions
decreases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GPX2 mRNA
Atazanavir Sulfate results in decreased expression of GPX2 mRNA

PMID:32152650 PMID:33819548

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glutathione S-transferase alpha 1

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of GSTA1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase mu 4

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA

NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323

G

2-hydroxyacyl-CoA lyase 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HACL1 mRNA

NCBI chr16:6,826,881...6,863,027
Ensembl chr16:6,824,906...6,863,027

G

hepatocyte growth factor

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HGF mRNA

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

G

heme oxygenase 1

multiple interactions
increases expression

Atazanavir Sulfate promotes the reaction [HMOX1 protein results in increased chemical synthesis of Bilirubin]; Ritonavir promotes the reaction [Atazanavir Sulfate results in increased expression of HMOX1 mRNA]
Atazanavir Sulfate results in increased expression of HMOX1 mRNA; Atazanavir Sulfate results in increased expression of HMOX1 protein

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

hemopexin

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HPX mRNA

NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328

G

heat shock protein family A (Hsp70) member 5

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of HSPA5 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

intercellular adhesion molecule 1

increases expression

Atazanavir Sulfate results in increased expression of ICAM1 protein

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

immediate early response 3

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IER3 mRNA

NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583

G

interferon, alpha-inducible protein 27

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IFI27 mRNA

NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294

G

insulin-like growth factor binding protein 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IGFBP1 mRNA

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

interleukin 6

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of IL6 mRNA

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunD proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA

NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799

G

kynureninase

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of KYNU mRNA

NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488

G

lipopolysaccharide binding protein

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LBP mRNA

NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586

G

low density lipoprotein receptor

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LDLR mRNA

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

lipase C, hepatic type

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LIPC mRNA

NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464

G

lymphocyte antigen 96

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LY96 mRNA

NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386

G

MAF bZIP transcription factor F

increases expression
multiple interactions

Atazanavir Sulfate results in increased expression of MAFF mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA

NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA
Atazanavir Sulfate results in increased expression of MAP1LC3B mRNA

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen-activated protein kinase kinase 6

multiple interactions
decreases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA
Atazanavir Sulfate results in decreased expression of MAP2K6 mRNA

NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293

G

MAPK activated protein kinase 3

increases expression
multiple interactions

Atazanavir Sulfate results in increased expression of MAPKAPK3 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA

NCBI chr 8:107,929,754...107,963,638
Ensembl chr 8:107,929,762...107,963,568

G

mixed lineage kinase domain like pseudokinase

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of MLKL mRNA
Atazanavir Sulfate results in increased expression of MLKL mRNA

PMID:32152650 PMID:33819548

NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502

G

methylmalonyl-CoA mutase

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MMUT mRNA

NCBI chr 9:19,928,720...19,956,985
Ensembl chr 9:19,928,727...19,957,046

G

microsomal triglyceride transfer protein

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MTTP mRNA

NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239

G

nuclear transcription factor, X-box binding-like 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of NFXL1 mRNA

NCBI chr14:35,626,086...35,667,505
Ensembl chr14:35,626,066...35,667,498

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of NR1H3 mRNA

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 1, group H, member 4

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of NR1H4 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 1, group I, member 2

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of NR1I2 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions
decreases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA
Atazanavir Sulfate results in decreased expression of NR1I3 mRNA

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

phenylalanine hydroxylase

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PAH mRNA

NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130

G

phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of PIK3C2G mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA

NCBI chr 4:172,483,752...172,851,623
Ensembl chr 4:172,484,345...172,850,544

G

phosphoinositide-3-kinase regulatory subunit 1

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of PIK3R1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA

NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631

G

paraoxonase 1

decreases activity

Atazanavir Sulfate results in decreased activity of PON1 protein

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

peroxisome proliferator activated receptor alpha

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

protein phosphatase 1, regulatory subunit 3C

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPP1R3C mRNA

NCBI chr 1:234,460,958...234,465,961
Ensembl chr 1:234,460,652...234,465,961

G

RAS like proto-oncogene A

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA

NCBI chr17:47,092,163...47,145,192
Ensembl chr17:47,092,207...47,144,063

G

receptor accessory protein 5

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of REEP5 mRNA

NCBI chr18:25,945,375...25,983,271
Ensembl chr18:25,945,381...25,976,509

G

receptor interacting serine/threonine kinase 1

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA

NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824

G

sterol carrier protein 2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SCP2 mRNA

NCBI chr 5:122,806,949...122,881,259
Ensembl chr 5:122,776,549...122,881,287

G

syndecan 2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SDC2 mRNA

NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081

G

serpin family E member 1

increases expression
multiple interactions

Atazanavir Sulfate results in increased expression of SERPINE1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

SH3 domain -containing GRB2-like endophilin B1

increases expression
multiple interactions

Atazanavir Sulfate results in increased expression of SH3GLB1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA

NCBI chr 2:233,750,838...233,784,817
Ensembl chr 2:233,750,838...233,784,784

G

solute carrier family 10 member 1

multiple interactions
decreases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA
Atazanavir Sulfate results in decreased expression of SLC10A1 mRNA

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 17 member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC17A1 mRNA

NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304

G

solute carrier family 22 member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC22A1 mRNA

NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678

G

solute carrier family 51 member A

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA

NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485

G

SLC51 subunit beta

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA

NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145

G

superoxide dismutase 2

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA
Atazanavir Sulfate results in increased expression of SOD2 mRNA

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

sortilin related receptor 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SORL1 mRNA

NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513

G

sequestosome 1

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA
Atazanavir Sulfate results in increased expression of SQSTM1 mRNA

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

sterol regulatory element binding transcription factor 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SREBF1 mRNA

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

signal recognition particle 72

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of SRP72 mRNA

NCBI chr14:31,168,175...31,195,717
Ensembl chr14:31,168,293...31,195,729

G

sulfotransferase family 2A member 1

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of SULT2A1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA

NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134

G

tissue factor pathway inhibitor

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TFPI mRNA

NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880

G

toll-like receptor 4

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TLR4 mRNA

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

TNF receptor superfamily member 10b

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFRSF10A mRNA

NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467

G

TNF superfamily member 10

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of TNFSF10 mRNA

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

TNF superfamily member 11

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFSF11 mRNA

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

benserazide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catechol-O-methyltransferase

increases methylation

COMT protein results in increased methylation of Benserazide

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

dopa decarboxylase

multiple interactions

Benserazide binds to and results in decreased activity of DDC protein

NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208

G

dopamine receptor D1

multiple interactions

[Oxidopamine co-treated with levodopa methyl ester] promotes the reaction [Benserazide results in increased expression of DRD1 protein]

NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002

G

dopamine receptor D2

multiple interactions

[Oxidopamine co-treated with levodopa methyl ester] inhibits the reaction [Benserazide results in increased expression of DRD2 protein]

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

benzohydrazide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

myeloperoxidase

decreases activity
multiple interactions

benzoylhydrazine results in decreased activity of MPO protein
benzoylhydrazine inhibits the reaction [MPO protein results in increased oxidation of 3,3',5,5'-tetramethylbenzidine]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

carbonyl dihydrazine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 14 member 1 (Kidd blood group)

affects transport

SLC14A1 protein affects the transport of carbohydrazide

NCBI chr18:71,565,453...71,608,807
Ensembl chr18:71,565,454...71,595,146

elesclomol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BAG cochaperone 3

increases expression
multiple interactions

elesclomol results in increased expression of BAG3 mRNA
Acetylcysteine inhibits the reaction [elesclomol results in increased expression of BAG3 mRNA]

NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858

G

cysteine and histidine rich domain containing 1

increases expression

elesclomol results in increased expression of CHORDC1 mRNA

NCBI chr 8:15,374,356...15,398,436
Ensembl chr 8:15,374,471...15,399,162

G

CDC-like kinase 1

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of CLK1 mRNA]

NCBI chr 9:59,947,774...59,959,002
Ensembl chr 9:59,947,764...59,957,000

G

crystallin, alpha B

increases expression

elesclomol results in increased expression of CRYAB mRNA

NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157

G

DnaJ heat shock protein family (Hsp40) member B1

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of DNAJB1 mRNA]

NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458

G

DnaJ heat shock protein family (Hsp40) member B4

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of DNAJB4 mRNA]

NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089

G

DnaJ heat shock protein family (Hsp40) member B9

increases expression

elesclomol results in increased expression of DNAJB9 mRNA

NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063

G

ferritin light chain 1

increases expression

elesclomol results in increased expression of FTL mRNA

NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725
Ensembl chr 2:95,936,387...95,939,725

G

glutamate cysteine ligase, modifier subunit

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of GCLM mRNA]

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

galactosidase, alpha

increases expression

elesclomol results in increased expression of GLA mRNA

NCBI chr X:97,769,227...97,780,646
Ensembl chr X:97,768,996...97,780,664

G

homocysteine inducible ER protein with ubiquitin like domain 1

increases expression
multiple interactions

elesclomol results in increased expression of HERPUD1 mRNA
Acetylcysteine inhibits the reaction [elesclomol results in increased expression of HERPUD1 mRNA]

NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424

G

heme oxygenase 1

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of HMOX1 mRNA]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock transcription factor 1

increases activity

elesclomol results in increased activity of HSF1 protein

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

heat shock protein family A (Hsp70) member 1A

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of HSPA1A mRNA]

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

heat shock protein family A (Hsp70) member 1B

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of HSPA1B mRNA]

NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
Ensembl chr20:3,856,006...3,873,240

G

heat shock protein family A (Hsp70) member 6 like, pseudogene 1

increases expression

elesclomol results in increased expression of HSPA6 mRNA

NCBI chr13:83,273,176...83,274,317

G

heat shock protein family H (Hsp110) member 1

increases expression

elesclomol results in increased expression of HSPH1 mRNA

NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224

G

immediate early response 5

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of IER5 mRNA]

NCBI chr13:67,270,134...67,272,226
Ensembl chr13:67,270,135...67,272,227

G

interferon-related developmental regulator 1

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of IFRD1 mRNA]

NCBI chr 6:57,269,395...57,317,833
Ensembl chr 6:57,269,384...57,288,990

G

metallothionein 1, pseudogene 3

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of MT1E mRNA]

NCBI chr17:74,786,652...74,787,040
Ensembl chr17:74,786,654...74,787,135

G

oxidative stress responsive serine-rich 1

increases expression
multiple interactions

elesclomol results in increased expression of OSER1 mRNA
Acetylcysteine inhibits the reaction [elesclomol results in increased expression of OSER1 mRNA]

NCBI chr 3:152,066,975...152,085,180
Ensembl chr 3:152,066,975...152,085,149

G

phorbol-12-myristate-13-acetate-induced protein 1

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of PMAIP1 mRNA]

NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429

G

protein phosphatase 1, regulatory subunit 15A

increases expression

elesclomol results in increased expression of PPP1R15A mRNA

NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171

G

proteasome 26S subunit, ATPase 1

increases expression

elesclomol results in increased expression of PSMC1 mRNA

NCBI chr 6:119,392,833...119,405,233
Ensembl chr 6:119,392,855...119,410,123

G

proteasome 26S subunit, ATPase 4

increases expression

elesclomol results in increased expression of PSMC4 mRNA

NCBI chr 1:83,349,127...83,357,497
Ensembl chr 1:83,348,592...83,357,494

G

proteasome 26S subunit, ATPase 6

increases expression

elesclomol results in increased expression of PSMC6 mRNA

NCBI chr15:18,542,585...18,564,057
Ensembl chr15:18,542,563...18,564,055

G

proteasome 26S subunit, non-ATPase 1

increases expression

elesclomol results in increased expression of PSMD1 mRNA

NCBI chr 9:86,709,714...86,785,213
Ensembl chr 9:86,709,947...86,785,211

G

proteasome 26S subunit, non-ATPase 12

increases expression

elesclomol results in increased expression of PSMD12 mRNA

NCBI chr10:92,438,223...92,457,323
Ensembl chr10:92,438,298...92,457,287

G

proteasome 26S subunit ubiquitin receptor, non-ATPase 2

increases expression

elesclomol results in increased expression of PSMD2 mRNA

NCBI chr11:80,248,364...80,258,991
Ensembl chr11:80,248,364...80,259,043

G

proteasome activator subunit 4

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of PSME4 mRNA]

NCBI chr14:104,505,716...104,609,410
Ensembl chr14:104,505,716...104,609,408

G

RB1-inducible coiled-coil 1

increases expression

elesclomol results in increased expression of RB1CC1 mRNA

NCBI chr 5:13,161,648...13,225,560
Ensembl chr 5:13,161,648...13,225,560

G

spermidine/spermine N1-acetyl transferase 1

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of SAT1 mRNA]

NCBI chr X:40,158,354...40,161,641
Ensembl chr X:40,157,046...40,196,813

G

SDE2 telomere maintenance homolog

increases expression

elesclomol results in increased expression of SDE2 mRNA

NCBI chr13:92,578,843...92,595,142
Ensembl chr13:92,578,874...92,595,140

G

solute carrier family 19 member 2

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of SLC19A2 mRNA]

NCBI chr13:76,601,975...76,616,175
Ensembl chr13:76,601,900...76,616,172

G

solute carrier family 30 member 1

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of SLC30A1 mRNA]

NCBI chr13:103,491,037...103,494,910
Ensembl chr13:103,491,037...103,494,910

G

solute carrier family 7 member 11

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of SLC7A11 mRNA]

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

tribbles pseudokinase 3

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of TRIB3 mRNA]

NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497

G

thioredoxin reductase 1

increases expression

elesclomol results in increased expression of TXNRD1 mRNA

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

G

ubiquitin-fold modifier 1

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of UFM1 mRNA]

NCBI chr 2:137,969,476...137,977,620
Ensembl chr 2:137,966,678...137,978,089
Ensembl chr 2:137,966,678...137,978,089

G

ubiquitin specific peptidase like 1

increases expression
multiple interactions

elesclomol results in increased expression of USPL1 mRNA
Acetylcysteine inhibits the reaction [elesclomol results in increased expression of USPL1 mRNA]

NCBI chr12:5,823,460...5,850,470
Ensembl chr12:5,823,359...5,850,366

G

yrdC N(6)-threonylcarbamoyltransferase domain containing

increases expression

elesclomol results in increased expression of YRDC mRNA

NCBI chr 5:137,110,244...137,115,127
Ensembl chr 5:137,110,279...137,115,120

G

zinc finger CCCH-type containing, antiviral 1

increases expression

elesclomol results in increased expression of ZC3HAV1 mRNA

NCBI chr 4:67,012,129...67,062,428
Ensembl chr 4:67,012,185...67,062,428

G

zinc finger AN1-type containing 2A

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of ZFAND2A mRNA]

NCBI chr12:15,161,601...15,172,679
Ensembl chr12:15,161,639...15,172,677

G

zinc finger protein 394

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [elesclomol results in increased expression of ZNF394 mRNA]

NCBI chr12:9,409,047...9,417,228
Ensembl chr12:9,409,078...9,417,246

fenamidone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions
increases expression

sulforaphane inhibits the reaction [fenamidone results in increased expression of ABCA1 mRNA]

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

acyl-CoA dehydrogenase, long chain

increases expression

fenamidone results in increased expression of ACADL mRNA

NCBI chr 9:68,333,981...68,372,149
Ensembl chr 9:68,333,980...68,372,220

G

acyl-CoA dehydrogenase short chain

increases expression

fenamidone results in increased expression of ACADS mRNA

NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898

G

acyl-CoA dehydrogenase, very long chain

increases expression

fenamidone results in increased expression of ACADVL mRNA

NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075

G

acyl-CoA synthetase bubblegum family member 1

increases expression

fenamidone results in increased expression of ACSBG1 mRNA

NCBI chr 8:54,991,294...55,047,276
Ensembl chr 8:54,991,296...55,047,391

G

actin alpha 2, smooth muscle

multiple interactions
increases expression

sulforaphane inhibits the reaction [fenamidone results in increased expression of ACTA2 mRNA]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

actinin, alpha 1

increases expression

fenamidone results in increased expression of ACTN1 mRNA

NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

increases expression

fenamidone results in increased expression of ADAMTS1 mRNA

NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103

G

ADAM metallopeptidase with thrombospondin type 1 motif, 5

increases expression

fenamidone results in increased expression of ADAMTS5 mRNA

NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205

G

ADAMTS-like 4

increases expression

fenamidone results in increased expression of ADAMTSL4 mRNA

NCBI chr 2:183,235,634...183,247,091
Ensembl chr 2:183,235,646...183,246,848

G

adenosine deaminase RNA specific B2

decreases expression

fenamidone results in decreased expression of ADARB2 mRNA

NCBI chr17:61,750,437...62,300,984
Ensembl chr17:61,756,067...62,300,831

G

adhesion G protein-coupled receptor E5

increases expression

fenamidone results in increased expression of ADGRE5 mRNA

NCBI chr19:24,397,972...24,418,648
Ensembl chr19:24,398,689...24,418,638

G

adhesion G protein-coupled receptor G6

increases expression

fenamidone results in increased expression of ADGRG6 mRNA

NCBI chr 1:8,812,889...8,954,239
Ensembl chr 1:8,812,904...8,954,123

G

adrenoceptor beta 2

increases expression

fenamidone results in increased expression of ADRB2 mRNA

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

AHNAK nucleoprotein

increases expression

fenamidone results in increased expression of AHNAK mRNA

NCBI chr 1:205,882,225...205,970,934
Ensembl chr 1:205,882,273...205,970,926

G

ajuba LIM protein

increases expression

fenamidone results in increased expression of AJUBA mRNA

NCBI chr15:28,019,775...28,031,537
Ensembl chr15:28,019,778...28,030,021

G

aldehyde dehydrogenase 4 family, member A1

increases expression

fenamidone results in increased expression of ALDH4A1 mRNA

NCBI chr 5:151,880,002...151,905,491
Ensembl chr 5:151,830,701...151,925,345

G

angiomotin-like 1

increases expression

fenamidone results in increased expression of AMOTL1 mRNA

NCBI chr 8:11,348,651...11,467,564
Ensembl chr 8:11,353,674...11,467,573

G

angiomotin like 2

increases expression

fenamidone results in increased expression of AMOTL2 mRNA

NCBI chr 8:103,303,368...103,319,161
Ensembl chr 8:103,302,992...103,318,910

G

angiopoietin-like 2

increases expression

fenamidone results in increased expression of ANGPTL2 mRNA

NCBI chr 3:16,517,185...16,547,024
Ensembl chr 3:16,517,420...16,548,178

G

ankyrin repeat and sterile alpha motif domain containing 1B

decreases expression

fenamidone results in decreased expression of ANKS1B mRNA

NCBI chr 7:24,313,339...25,479,307
Ensembl chr 7:24,312,843...25,477,693

G

annexin A2

increases expression

fenamidone results in increased expression of ANXA2 mRNA

NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658

G

annexin A3

increases expression

fenamidone results in increased expression of ANXA3 mRNA

NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617

G

Rho GTPase activating protein 18

increases expression

fenamidone results in increased expression of ARHGAP18 mRNA

NCBI chr 1:18,403,531...18,637,306
Ensembl chr 1:18,403,537...18,637,256

G

actin related protein 2/3 complex, subunit 1B

increases expression

fenamidone results in increased expression of ARPC1B mRNA

NCBI chr12:9,482,176...9,495,772
Ensembl chr12:9,480,831...9,495,747

G

N-acylsphingosine amidohydrolase 1

increases expression

fenamidone results in increased expression of ASAH1 mRNA

NCBI chr16:50,966,404...50,997,827
Ensembl chr16:50,966,229...51,008,233

G

argininosuccinate synthase 1

increases expression

fenamidone results in increased expression of ASS1 mRNA

NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903

G

activating transcription factor 3

increases expression

fenamidone results in increased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 5

increases expression

fenamidone results in increased expression of ATF5 mRNA

NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707

G

atlastin GTPase 1

decreases expression

fenamidone results in decreased expression of ATL1 mRNA

NCBI chr 6:88,377,168...88,475,242
Ensembl chr 6:88,377,239...88,475,204

G

ATPase H+ transporting V0 subunit D2

increases expression

fenamidone results in increased expression of ATP6V0D2 mRNA

NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354

G

ATPase H+ transporting V0 subunit e1

increases expression

fenamidone results in increased expression of ATP6V0E mRNA

NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434

G

Axl receptor tyrosine kinase

increases expression

fenamidone results in increased expression of AXL mRNA

NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265

G

BAG cochaperone 3

increases expression

fenamidone results in increased expression of BAG3 mRNA

NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858

G

BCL11 transcription factor B

decreases expression

fenamidone results in decreased expression of BCL11B mRNA

NCBI chr 6:126,834,531...126,927,720
Ensembl chr 6:126,834,531...126,928,224

G

brain expressed, associated with NEDD4, 1

decreases expression

fenamidone results in decreased expression of BEAN1 mRNA

NCBI chr19:739,551...786,395
Ensembl chr19:739,551...787,537

G

basic helix-loop-helix family, member e41

increases expression

fenamidone results in increased expression of BHLHE41 mRNA

NCBI chr 4:178,834,264...178,838,618
Ensembl chr 4:178,834,271...178,838,468

G

BCL2 interacting protein 3

decreases expression

fenamidone results in decreased expression of BNIP3 mRNA

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

BTG anti-proliferation factor 2

increases expression

fenamidone results in increased expression of BTG2 mRNA

NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628

G

calcium dependent secretion activator

decreases expression

fenamidone results in decreased expression of CADPS mRNA

NCBI chr15:12,289,803...12,742,786
Ensembl chr15:12,290,262...12,742,779

G

caldesmon 1

increases expression

fenamidone results in increased expression of CALD1 mRNA

NCBI chr 4:63,265,781...63,446,938
Ensembl chr 4:63,265,942...63,446,932

G

calcium/calmodulin-dependent protein kinase IV

decreases expression

fenamidone results in decreased expression of CAMK4 mRNA

NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487

G

calmodulin binding transcription activator 1

decreases expression

fenamidone results in decreased expression of CAMTA1 mRNA

NCBI chr 5:161,510,283...162,356,902
Ensembl chr 5:161,510,283...162,356,723

G

carbonic anhydrase 2

increases expression

fenamidone results in increased expression of CAR2 mRNA

NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818

G

cask-interacting protein 2

increases expression

fenamidone results in increased expression of CASKIN2 mRNA

NCBI chr10:101,027,196...101,041,429
Ensembl chr10:101,027,260...101,041,414

G

caveolae associated protein 1

increases expression

fenamidone results in increased expression of CAVIN1 mRNA

NCBI chr10:85,884,100...85,896,136
Ensembl chr10:85,889,036...85,896,120

G

carbonyl reductase 3

increases expression

fenamidone results in increased expression of CBR3 mRNA

NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875

G

coiled-coil domain containing 141

increases expression

fenamidone results in increased expression of CCDC141 mRNA

NCBI chr 3:61,948,614...62,109,968
Ensembl chr 3:61,948,646...62,110,079

G

cholecystokinin

decreases expression

fenamidone results in decreased expression of CCK mRNA

NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084

G

cellular communication network factor 1

increases expression

fenamidone results in increased expression of CCN1 mRNA

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

cyclin D2

increases expression

fenamidone results in increased expression of CCND2 mRNA

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

cyclin D3

increases expression

fenamidone results in increased expression of CCND3 mRNA

NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371

G

cyclin G1

increases expression

fenamidone results in increased expression of CCNG1 mRNA

NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641

G

centriole, cilia and spindle-associated protein

decreases expression

fenamidone results in decreased expression of CCSAP mRNA

NCBI chr19:51,824,954...51,843,469
Ensembl chr19:51,826,994...51,842,753

G

CD151 molecule (Raph blood group)

increases expression

fenamidone results in increased expression of CD151 mRNA

NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753

G

Cd63 molecule

increases expression

fenamidone results in increased expression of CD63 mRNA

NCBI chr 7:1,325,108...1,340,447
Ensembl chr 7:1,325,103...1,399,178

G

Cd68 molecule

increases expression

fenamidone results in increased expression of CD68 mRNA

NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697

G

CDC42 effector protein 1

increases expression

fenamidone results in increased expression of CDC42EP1 mRNA

NCBI chr 7:110,395,287...110,403,203
Ensembl chr 7:110,395,332...110,403,200

G

cyclin-dependent kinase inhibitor 1A

increases expression

fenamidone results in increased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1C

increases expression

fenamidone results in increased expression of CDKN1C mRNA

NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048

G

CCAAT/enhancer binding protein beta

increases expression

fenamidone results in increased expression of CEBPB mRNA

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

cell migration inducing hyaluronidase 1

increases expression

fenamidone results in increased expression of CEMIP mRNA

NCBI chr 1:137,906,921...138,062,430
Ensembl chr 1:137,908,920...138,062,415

G

cerebral endothelial cell adhesion molecule

increases expression

fenamidone results in increased expression of CERCAM mRNA

NCBI chr 3:13,118,150...13,155,960
Ensembl chr 3:13,142,107...13,155,956

G

ChaC glutathione-specific gamma-glutamylcyclotransferase 1

increases expression

fenamidone results in increased expression of CHAC1 mRNA

NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526

G

carbohydrate sulfotransferase 3

increases expression

fenamidone results in increased expression of CHST3 mRNA

NCBI chr20:28,114,386...28,152,046
Ensembl chr20:28,114,404...28,121,807

G

creatine kinase B

increases expression

fenamidone results in increased expression of CKB mRNA

NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315

G

C-type lectin domain containing 7A

increases expression

fenamidone results in increased expression of CLEC7A mRNA

NCBI chr 4:162,902,731...162,913,931
Ensembl chr 4:162,902,732...162,913,897

G

chloride intracellular channel 1

increases expression

fenamidone results in increased expression of CLIC1 mRNA

NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712

G

CLN5, intracellular trafficking protein

increases expression

fenamidone results in increased expression of CLN5 mRNA

NCBI chr15:79,893,573...79,903,438
Ensembl chr15:79,893,548...79,903,438
Ensembl chr 2:79,893,548...79,903,438

G

calsyntenin 3

decreases expression

fenamidone results in decreased expression of CLSTN3 mRNA

NCBI chr 4:157,331,494...157,364,769
Ensembl chr 4:157,331,494...157,364,769

G

CKLF-like MARVEL transmembrane domain containing 3

increases expression

fenamidone results in increased expression of CMTM3 mRNA

NCBI chr19:622,563...630,721
Ensembl chr19:604,458...629,790

G

calponin 2

increases expression

fenamidone results in increased expression of CNN2 mRNA

NCBI chr 7:9,712,505...9,719,678
Ensembl chr 7:9,712,516...9,719,656

G

contactin associated protein family member 4

decreases expression

fenamidone results in decreased expression of CNTNAP4 mRNA

NCBI chr19:40,568,684...40,861,879
Ensembl chr19:40,568,684...40,854,656

G

collagen type XI alpha 1 chain

increases expression

fenamidone results in increased expression of COL11A1 mRNA

NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853

G

collagen type XII alpha 1 chain

increases expression

fenamidone results in increased expression of COL12A1 mRNA

NCBI chr 8:80,547,592...80,665,665
Ensembl chr 8:80,547,593...80,665,686

G

collagen type IV alpha 5 chain

increases expression

fenamidone results in increased expression of COL4A5 mRNA

NCBI chr X:105,118,762...105,322,699
Ensembl chr X:105,118,820...105,322,692

G

collagen type IV alpha 6 chain

increases expression

fenamidone results in increased expression of COL4A6 mRNA

NCBI chr X:104,766,463...105,117,499
Ensembl chr X:104,766,957...105,117,500

G

collagen type VIII alpha 1 chain

increases expression

fenamidone results in increased expression of COL8A1 mRNA

NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424

G

cytoplasmic polyadenylation element binding protein 1

increases expression

fenamidone results in increased expression of CPEB1 mRNA

NCBI chr 1:135,300,048...135,407,688
Ensembl chr 1:135,300,461...135,409,760

G

complexin 1

decreases expression

fenamidone results in decreased expression of CPLX1 mRNA

NCBI chr14:1,184,677...1,216,392

G

carnitine palmitoyltransferase 1A

increases expression

fenamidone results in increased expression of CPT1A mRNA

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

cartilage associated protein

increases expression

fenamidone results in increased expression of CRTAP mRNA

NCBI chr 8:114,047,929...114,067,636
Ensembl chr 8:114,047,933...114,067,631

G

colony stimulating factor 1

increases expression

fenamidone results in increased expression of CSF1 mRNA

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

cysteine and glycine-rich protein 1

increases expression

fenamidone results in increased expression of CSRP1 mRNA

NCBI chr13:47,158,171...47,179,388
Ensembl chr13:47,167,789...47,179,384

G

cystatin B

increases expression

fenamidone results in increased expression of CSTB mRNA

NCBI chr20:10,245,462...10,247,505
Ensembl chr20:10,245,462...10,247,526

G

catenin alpha 1

increases expression

fenamidone results in increased expression of CTNNA1 mRNA

NCBI chr18:26,728,246...26,860,911
Ensembl chr18:26,728,485...26,860,910

G

cathepsin D

increases expression

fenamidone results in increased expression of CTSD mRNA

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

cathepsin L

increases expression

fenamidone results in increased expression of CTSL mRNA

NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548

G

cathepsin Z

increases expression

fenamidone results in increased expression of CTSZ mRNA

NCBI chr 3:163,224,875...163,235,645
Ensembl chr 3:163,224,875...163,235,645

G

cytochrome b-245 alpha chain

increases expression

fenamidone results in increased expression of CYBA mRNA

NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721

G

dishevelled associated activator of morphogenesis 2

increases expression

fenamidone results in increased expression of DAAM2 mRNA

NCBI chr 9:11,428,913...11,546,982
Ensembl chr 9:11,428,724...11,545,497

G

DAB adaptor protein 2

increases expression

fenamidone results in increased expression of DAB2 mRNA

NCBI chr 2:55,514,692...55,567,476
Ensembl chr 2:55,514,700...55,567,476

G

dicarbonyl and L-xylulose reductase

increases expression

fenamidone results in increased expression of DCXR mRNA

NCBI chr10:106,006,404...106,008,293

G

discoidin domain receptor tyrosine kinase 2

increases expression

fenamidone results in increased expression of DDR2 mRNA

NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363

G

DENN domain containing 2B

increases expression

fenamidone results in increased expression of DENND2B mRNA

NCBI chr 1:163,544,075...163,734,736
Ensembl chr 1:163,544,074...163,694,680

G

DNA fragmentation factor subunit alpha

decreases expression

fenamidone results in decreased expression of DFFA mRNA

NCBI chr 5:159,540,715...159,553,639
Ensembl chr 5:159,540,715...159,553,633

G

dynamin 3

decreases expression

fenamidone results in decreased expression of DNM3 mRNA

NCBI chr13:74,359,043...74,838,135
Ensembl chr13:74,359,213...74,838,108

G

dedicator of cyto-kinesis 1

increases expression

fenamidone results in increased expression of DOCK1 mRNA

NCBI chr 1:189,467,143...189,983,777
Ensembl chr 1:189,467,143...189,983,768

G

dipeptidyl peptidase like 10

decreases expression

fenamidone results in decreased expression of DPP10 mRNA

NCBI chr13:34,584,420...36,269,292
Ensembl chr13:34,595,868...36,269,292

G

enoyl-CoA delta isomerase 2

increases expression

fenamidone results in increased expression of ECI2 mRNA

NCBI chr17:29,850,884...29,886,781
Ensembl chr17:29,870,391...29,886,781

G

ectodysplasin A2 receptor

increases expression

fenamidone results in increased expression of EDA2R mRNA

NCBI chr X:62,224,763...62,269,333
Ensembl chr X:62,228,229...62,269,268

G

eukaryotic translation elongation factor 1 alpha 2

decreases expression

fenamidone results in decreased expression of EEF1A2 mRNA

NCBI chr 3:168,265,893...168,275,071
Ensembl chr 3:168,195,357...168,275,071

G

EGF containing fibulin extracellular matrix protein 1

increases expression

fenamidone results in increased expression of EFEMP1 mRNA

NCBI chr14:102,610,813...102,690,027
Ensembl chr14:102,610,908...102,690,018

G

epidermal growth factor receptor

increases expression

fenamidone results in increased expression of EGFR mRNA

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

EH-domain containing 2

increases expression

fenamidone results in increased expression of EHD2 mRNA

NCBI chr 1:76,639,568...76,658,747
Ensembl chr 1:76,637,482...76,658,783

G

EH-domain containing 4

increases expression

fenamidone results in increased expression of EHD4 mRNA

NCBI chr 3:107,058,191...107,121,985
Ensembl chr 3:107,058,958...107,122,002

G

eukaryotic translation initiation factor 4E binding protein 1

increases expression

fenamidone results in increased expression of EIF4EBP1 mRNA

NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984

G

ELAV like RNA binding protein 2

decreases expression

fenamidone results in decreased expression of ELAVL2 mRNA

NCBI chr 5:105,960,872...106,086,463
Ensembl chr 5:105,960,875...106,109,097

G

ETS transcription factor ELK3

increases expression

fenamidone results in increased expression of ELK3 mRNA

NCBI chr 7:27,768,582...27,831,088
Ensembl chr 7:27,768,599...27,804,084

G

elastin

increases expression

fenamidone results in increased expression of ELN mRNA

NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928

G

ELOVL fatty acid elongase 1

increases expression

fenamidone results in increased expression of ELOVL1 mRNA

NCBI chr 5:131,961,478...131,965,961
Ensembl chr 5:131,961,322...131,965,958

G

ecto-NOX disulfide-thiol exchanger 1

decreases expression

fenamidone results in decreased expression of ENOX1 mRNA

NCBI chr15:52,517,833...53,079,752
Ensembl chr15:52,515,178...53,079,749

G

endothelial PAS domain protein 1

increases expression

fenamidone results in increased expression of EPAS1 mRNA

NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228

G

Eph receptor A2

increases expression

fenamidone results in increased expression of EPHA2 mRNA

NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117

G

epoxide hydrolase 1

increases expression

fenamidone results in increased expression of EPHX1 mRNA

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

electron transfer flavoprotein subunit beta

increases expression

fenamidone results in increased expression of ETFB mRNA

NCBI chr 1:93,851,908...93,866,072
Ensembl chr 1:93,851,858...93,866,068

G

ETS proto-oncogene 1, transcription factor

increases expression

fenamidone results in increased expression of ETS1 mRNA

NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010

G

EvC ciliary complex subunit 1

increases expression

fenamidone results in increased expression of EVC mRNA

NCBI chr14:73,456,181...73,498,955
Ensembl chr14:73,456,222...73,498,099

G

coagulation factor II (thrombin) receptor

increases expression

fenamidone results in increased expression of F2R mRNA

NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870

G

coagulation factor III, tissue factor

increases expression

fenamidone results in increased expression of F3 mRNA

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

Fas apoptotic inhibitory molecule 2

decreases expression

fenamidone results in decreased expression of FAIM2 mRNA

NCBI chr 7:130,632,368...130,659,353
Ensembl chr 7:130,633,348...130,659,168

G

FAT atypical cadherin 1

increases expression

fenamidone results in increased expression of FAT1 mRNA

NCBI chr16:47,177,253...47,296,261
Ensembl chr16:47,177,248...47,296,107

G

fibrillin 1

increases expression

fenamidone results in increased expression of FBN1 mRNA

NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889

G

f-box protein 9

decreases expression

fenamidone results in decreased expression of FBXO9 mRNA

NCBI chr 8:78,958,482...78,984,015
Ensembl chr 8:78,958,483...78,983,949

G

Fibroblast growth factor receptor 1

increases expression

fenamidone results in increased expression of FGFR1 mRNA

NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350

G

fibroblast growth factor receptor 3

increases expression

fenamidone results in increased expression of FGFR3 mRNA

NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341

G

FKBP prolyl isomerase 10

increases expression

fenamidone results in increased expression of FKBP10 mRNA

NCBI chr10:85,345,434...85,357,998
Ensembl chr10:85,346,126...85,427,330

G

FKBP prolyl isomerase 9

increases expression

fenamidone results in increased expression of FKBP9 mRNA

NCBI chr 4:86,106,256...86,156,723
Ensembl chr 4:86,106,282...86,156,721

G

filamin A

increases expression

fenamidone results in increased expression of FLNA mRNA

NCBI chr X:152,007,758...152,034,266
Ensembl chr X:152,007,758...152,031,052

G

filamin B

increases expression

fenamidone results in increased expression of FLNB mRNA

NCBI chr15:16,961,999...17,095,059
Ensembl chr15:16,962,003...17,095,006

G

filamin C

increases expression

fenamidone results in increased expression of FLNC mRNA

NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844

G

fibronectin 1

increases expression

fenamidone results in increased expression of FN1 mRNA

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

FERM domain containing 8

increases expression

fenamidone results in increased expression of FRMD8 mRNA

NCBI chr 1:203,143,216...203,163,868
Ensembl chr 1:203,143,218...203,163,870

G

frizzled class receptor 7

increases expression

fenamidone results in increased expression of FZD7 mRNA

NCBI chr 9:60,931,433...60,934,252
Ensembl chr 9:60,930,875...60,935,781

G

glutamate decarboxylase 1

decreases expression

fenamidone results in decreased expression of GAD1 mRNA

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333

G

glutamate decarboxylase 2

decreases expression

fenamidone results in decreased expression of GAD2 mRNA

NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155

G

growth arrest and DNA-damage-inducible, alpha

increases expression

fenamidone results in increased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

polypeptide N-acetylgalactosaminyltransferase 9

decreases expression

fenamidone results in decreased expression of GALNT9 mRNA

NCBI chr12:46,050,395...46,128,626
Ensembl chr12:46,050,413...46,128,578

G

growth differentiation factor 15

increases expression

fenamidone results in increased expression of GDF15 mRNA

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

gap junction protein, delta 2

decreases expression

fenamidone results in decreased expression of GJD2 mRNA

NCBI chr 3:100,771,450...100,776,134
Ensembl chr 3:100,772,062...100,775,061

G

glycosylated lysosomal membrane protein

increases expression

fenamidone results in increased expression of GLMP mRNA

NCBI chr 2:173,794,273...173,797,863
Ensembl chr 2:173,794,255...173,799,960

G

glycine receptor, alpha 2

decreases expression

fenamidone results in decreased expression of GLRA2 mRNA

NCBI chr X:29,020,377...29,241,666
Ensembl chr X:29,020,557...29,241,666

G

glutaminase

decreases expression

fenamidone results in decreased expression of GLS mRNA

NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900

G

glycolipid transfer protein

increases expression

fenamidone results in increased expression of GLTP mRNA

NCBI chr12:41,907,168...41,927,321
Ensembl chr12:41,907,144...41,927,319

G

G protein subunit gamma 12

increases expression

fenamidone results in increased expression of GNG12 mRNA

NCBI chr 4:96,011,118...96,134,767
Ensembl chr 4:96,010,952...96,134,712

G

glycoprotein nmb

increases expression

fenamidone results in increased expression of GPNMB mRNA

NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367

G

G protein-coupled receptor 22

decreases expression

fenamidone results in decreased expression of GPR22 mRNA

NCBI chr 6:48,309,619...48,317,864
Ensembl chr 6:48,310,505...48,317,486

G

G-protein coupled receptor 88

decreases expression

fenamidone results in decreased expression of GPR88 mRNA

NCBI chr 2:204,191,443...204,199,576
Ensembl chr 2:204,191,427...204,199,733

G

glutathione peroxidase 1

increases expression

fenamidone results in increased expression of GPX1 mRNA

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutamate ionotropic receptor kainate type subunit 3

decreases expression

fenamidone results in decreased expression of GRIK3 mRNA

NCBI chr 5:137,767,865...137,989,617
Ensembl chr 5:137,767,865...137,984,307

G

granulin precursor

increases expression

fenamidone results in increased expression of GRN mRNA

NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775

G

glutathione synthetase

increases expression

fenamidone results in increased expression of GSS mRNA

NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198

G

glutathione S-transferase mu 1

multiple interactions
increases expression

sulforaphane inhibits the reaction [fenamidone results in increased expression of GSTM1 mRNA]

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

G-2 and S-phase expressed 1

increases expression

fenamidone results in increased expression of GTSE1 mRNA

NCBI chr 7:116,949,997...116,966,826
Ensembl chr 7:116,950,053...116,966,806

G

glucoside xylosyltransferase 2

increases expression

fenamidone results in increased expression of GXYLT2 mRNA

NCBI chr 4:133,347,230...133,449,708
Ensembl chr 4:133,347,499...133,449,454

G

3-hydroxyacyl-CoA dehydratase 4

increases expression

fenamidone results in increased expression of HACD4 mRNA

NCBI chr 5:102,887,597...102,915,376
Ensembl chr 5:102,887,588...102,915,338

G

hydroxyacyl-CoA dehydrogenase

increases expression

fenamidone results in increased expression of HADH mRNA

NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353

G

hyaluronan and proteoglycan link protein 1

decreases expression

fenamidone results in decreased expression of HAPLN1 mRNA

NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777

G

heparin-binding EGF-like growth factor

increases expression

fenamidone results in increased expression of HBEGF mRNA

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

heme oxygenase 1

multiple interactions
increases expression

sulforaphane inhibits the reaction [fenamidone results in increased expression of HMOX1 mRNA]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heparan sulfate-glucosamine 3-sulfotransferase 2

decreases expression

fenamidone results in decreased expression of HS3ST2 mRNA

NCBI chr 1:175,956,161...176,077,400
Ensembl chr 1:175,956,157...176,077,399

G

heparan sulfate proteoglycan 2

increases expression

fenamidone results in increased expression of HSPG2 mRNA

NCBI chr 5:149,677,437...149,778,594
Ensembl chr 5:149,677,476...149,778,594

G

hyaluronidase 1

increases expression

fenamidone results in increased expression of HYAL1 mRNA

NCBI chr 8:108,250,668...108,254,519
Ensembl chr 8:108,250,667...108,260,210

G

intercellular adhesion molecule 1

increases expression

fenamidone results in increased expression of ICAM1 mRNA

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

immediate early response 3

increases expression

fenamidone results in increased expression of IER3 mRNA

NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583

G

IFI30, lysosomal thiol reductase

increases expression

fenamidone results in increased expression of IFI30 mRNA

NCBI chr16:18,675,590...18,679,655
Ensembl chr16:18,675,613...18,681,175

G

interferon induced transmembrane protein 2

increases expression

fenamidone results in increased expression of IFITM2 mRNA

NCBI chr 1:196,051,539...196,052,719
Ensembl chr 1:196,051,537...196,052,741

G

immunoglobulin superfamily, DCC subclass, member 4

increases expression

fenamidone results in increased expression of IGDCC4 mRNA

NCBI chr 8:65,621,893...65,657,651
Ensembl chr 8:65,621,897...65,657,648

G

insulin-like growth factor binding protein 3

increases expression

fenamidone results in increased expression of IGFBP3 mRNA

NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083

G

insulin-like growth factor binding protein-like 1

increases expression

fenamidone results in increased expression of IGFBPL1 mRNA

NCBI chr 5:60,076,428...60,091,833
Ensembl chr 5:60,076,429...60,091,833

G

interleukin 1 receptor accessory protein

increases expression

fenamidone results in increased expression of IL1RAP mRNA

NCBI chr11:74,062,999...74,199,530
Ensembl chr11:74,070,304...74,199,530

G

inverted formin 2

increases expression

fenamidone results in increased expression of INF2 mRNA

NCBI chr 6:131,649,162...131,675,944
Ensembl chr 6:131,649,211...131,675,941

G

interaction protein for cytohesin exchange factors 1

decreases expression

fenamidone results in decreased expression of IPCEF1 mRNA

NCBI chr 1:43,237,903...43,451,735
Ensembl chr 1:43,269,202...43,427,969

G

interleukin-1 receptor-associated kinase 1

increases expression

fenamidone results in increased expression of IRAK1 mRNA

NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521

G

integrin subunit alpha 3

increases expression

fenamidone results in increased expression of ITGA3 mRNA

NCBI chr10:79,990,160...80,022,206
Ensembl chr10:79,990,161...80,022,118

G

integrin subunit alpha 5

increases expression

fenamidone results in increased expression of ITGA5 mRNA

NCBI chr 7:134,478,963...134,502,837
Ensembl chr 7:134,478,968...134,502,837

G

integrin subunit alpha 6

increases expression

fenamidone results in increased expression of ITGA6 mRNA

NCBI chr 3:56,604,512...56,689,428
Ensembl chr 3:56,617,268...56,689,428

G

integrin subunit alpha 7

increases expression

fenamidone results in increased expression of ITGA7 mRNA

NCBI chr 7:1,360,125...1,388,886
Ensembl chr 7:1,359,940...1,388,450

G

integrin subunit alpha V

increases expression

fenamidone results in increased expression of ITGAV mRNA

NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639

G

integrin subunit beta 1

increases expression

fenamidone results in increased expression of ITGB1 mRNA

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

ITPR interacting domain containing 2

increases expression

fenamidone results in increased expression of ITPRID2 mRNA

NCBI chr 3:64,536,707...64,573,978
Ensembl chr 3:64,536,707...64,573,978

G

KN motif and ankyrin repeat domains 4

increases expression

fenamidone results in increased expression of KANK4 mRNA

NCBI chr 5:113,401,491...113,465,526
Ensembl chr 5:113,402,468...113,465,555

G

potassium voltage-gated channel subfamily A member 1

decreases expression

fenamidone results in decreased expression of KCNA1 mRNA

NCBI chr 4:159,464,223...159,472,905
Ensembl chr 4:159,464,188...159,472,682

G

potassium voltage-gated channel subfamily C member 2

decreases expression

fenamidone results in decreased expression of KCNC2 mRNA

NCBI chr 7:47,700,035...47,883,979
Ensembl chr 7:47,700,288...47,883,968

G

potassium voltage-gated channel subfamily H member 3

decreases expression
multiple interactions

fenamidone results in decreased expression of KCNH3 mRNA
sulforaphane inhibits the reaction [fenamidone results in decreased expression of KCNH3 mRNA]

NCBI chr 7:130,365,593...130,383,859
Ensembl chr 7:130,366,011...130,383,855

G

potassium voltage-gated channel modifier subfamily V member 1

decreases expression

fenamidone results in decreased expression of KCNV1 mRNA

NCBI chr 7:76,260,695...76,269,170
Ensembl chr 7:76,260,695...76,269,170

G

kinesin family member 1C

increases expression

fenamidone results in increased expression of KIF1C mRNA

NCBI chr10:55,414,412...55,444,587
Ensembl chr10:55,415,900...55,443,545

G

kinesin family member 5A

decreases expression

fenamidone results in decreased expression of KIF5A mRNA

NCBI chr 7:63,051,894...63,089,024
Ensembl chr 7:63,049,424...63,092,858

G

kirre like nephrin family adhesion molecule 1

increases expression

fenamidone results in increased expression of KIRREL1 mRNA

NCBI chr 2:172,521,644...172,615,057
Ensembl chr 2:172,525,245...172,615,299

G

KLF transcription factor 3

increases expression

fenamidone results in increased expression of KLF3 mRNA

NCBI chr14:43,474,767...43,505,801
Ensembl chr14:43,474,767...43,497,209

G

KLF transcription factor 4

increases expression

fenamidone results in increased expression of KLF4 mRNA

NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602

G

laminin subunit alpha 5

increases expression

fenamidone results in increased expression of LAMA5 mRNA

NCBI chr 3:167,270,296...167,318,370
Ensembl chr 3:167,270,296...167,318,451

G

laminin subunit beta 1

increases expression

fenamidone results in increased expression of LAMB1 mRNA

NCBI chr 6:47,835,492...47,902,585
Ensembl chr 6:47,835,525...47,902,585

G

laminin subunit beta 2

increases expression

fenamidone results in increased expression of LAMB2 mRNA

NCBI chr 8:109,178,367...109,190,552
Ensembl chr 8:109,178,409...109,190,549

G

laminin subunit gamma 1

increases expression

fenamidone results in increased expression of LAMC1 mRNA

NCBI chr13:65,374,372...65,501,492
Ensembl chr13:65,374,372...65,501,492

G

large tumor suppressor kinase 2

increases expression

fenamidone results in increased expression of LATS2 mRNA

NCBI chr15:31,825,068...31,877,193
Ensembl chr15:31,825,092...31,877,220

G

galectin 1

increases expression

fenamidone results in increased expression of LGALS1 mRNA

NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345

G

galectin 3

increases expression

fenamidone results in increased expression of LGALS3 mRNA

NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025

G

leucine-rich, glioma inactivated 1

decreases expression

fenamidone results in decreased expression of LGI1 mRNA

NCBI chr 1:236,043,269...236,084,617
Ensembl chr 1:236,042,954...236,084,616

G

LHFPL tetraspan subfamily member 6

increases expression

fenamidone results in increased expression of LHFPL6 mRNA

NCBI chr 2:137,126,485...137,324,442
Ensembl chr 2:137,126,509...137,324,443

G

LIF, interleukin 6 family cytokine

increases expression

fenamidone results in increased expression of LIF mRNA

NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482

G

LIM domain and actin binding 1

multiple interactions
increases expression

sulforaphane inhibits the reaction [fenamidone results in increased expression of LIMA1 mRNA]

NCBI chr 7:130,901,717...131,001,512
Ensembl chr 7:130,901,717...131,001,473

G

lipase A, lysosomal acid type

increases expression

fenamidone results in increased expression of LIPA mRNA

NCBI chr 1:232,024,351...232,057,735
Ensembl chr 1:232,024,356...232,057,633

G

lipopolysaccharide-induced TNF factor

increases expression

fenamidone results in increased expression of LITAF mRNA

NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763

G

leiomodin 1

increases expression

fenamidone results in increased expression of LMOD1 mRNA

NCBI chr13:46,754,048...46,796,186
Ensembl chr13:46,754,033...46,794,900

G

LIM domain containing preferred translocation partner in lipoma

increases expression

fenamidone results in increased expression of LPP mRNA

NCBI chr11:75,787,326...76,426,646
Ensembl chr11:75,797,078...76,422,597

G

LDL receptor related protein 2

increases expression

fenamidone results in increased expression of LRP2 mRNA

NCBI chr 3:54,189,305...54,346,769
Ensembl chr 3:54,189,308...54,346,708

G

LDL receptor related protein 5

increases expression

fenamidone results in increased expression of LRP5 mRNA

NCBI chr 1:200,814,247...200,917,581
Ensembl chr 1:200,814,250...200,917,581

G

leucine-rich repeat kinase 1

increases expression

fenamidone results in increased expression of LRRK1 mRNA

NCBI chr 1:119,844,360...119,972,885
Ensembl chr 1:119,845,146...119,979,734

G

leucine-rich repeat kinase 2

increases expression

fenamidone results in increased expression of LRRK2 mRNA

NCBI chr 7:122,826,696...122,987,711
Ensembl chr 7:122,826,696...122,987,703

G

LSM11, U7 small nuclear RNA associated

decreases expression

fenamidone results in decreased expression of LSM11 mRNA

NCBI chr10:30,367,841...30,385,956
Ensembl chr10:30,370,727...30,385,944

G

leucine zipper tumor suppressor 1

decreases expression

fenamidone results in decreased expression of LZTS1 mRNA

NCBI chr16:20,542,756...20,598,204
Ensembl chr16:20,542,809...20,598,203

G

MAF bZIP transcription factor F

increases expression

fenamidone results in increased expression of MAFF mRNA

NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851

G

mannosidase, alpha, class 2B, member 1

increases expression

fenamidone results in increased expression of MAN2B1 mRNA

NCBI chr19:23,055,092...23,074,398
Ensembl chr19:23,055,097...23,074,389

G

mannosidase, alpha, class 2B, member 2

increases expression

fenamidone results in increased expression of MAN2B2 mRNA

NCBI chr14:73,969,079...73,994,089
Ensembl chr14:73,969,003...74,004,281

G

mitogen-activated protein kinase kinase kinase 20

increases expression

fenamidone results in increased expression of MAP3K20 mRNA

NCBI chr 3:57,130,539...57,289,943
Ensembl chr 3:57,130,551...57,289,626

G

MAPK activated protein kinase 3

increases expression

fenamidone results in increased expression of MAPKAPK3 mRNA

NCBI chr 8:107,929,754...107,963,638
Ensembl chr 8:107,929,762...107,963,568

G

minichromosome maintenance complex component 2

increases expression

fenamidone results in increased expression of MCM2 mRNA

NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847

G

midkine

increases expression

fenamidone results in increased expression of MDK mRNA

NCBI chr 3:77,901,134...77,903,997
Ensembl chr 3:77,901,158...77,903,130

G

moesin

increases expression

fenamidone results in increased expression of MSN mRNA

NCBI chr X:60,996,043...61,064,011
Ensembl chr X:60,995,951...61,065,628

G

methionine sulfoxide reductase B3

increases expression

fenamidone results in increased expression of MSRB3 mRNA

NCBI chr 7:56,260,985...56,426,004
Ensembl chr 7:56,303,308...56,425,496

G

methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1

increases expression

fenamidone results in increased expression of MTHFD1 mRNA

NCBI chr 6:94,977,862...95,045,375
Ensembl chr 6:94,977,862...95,045,372

G

MYB proto-oncogene like 1

increases expression

fenamidone results in increased expression of MYBL1 mRNA

NCBI chr 5:9,582,905...9,618,179
Ensembl chr 5:9,582,934...9,618,183

G

myosin, heavy chain 9

increases expression

fenamidone results in increased expression of MYH9 mRNA

NCBI chr 7:109,343,718...109,424,457
Ensembl chr 7:109,343,706...109,424,457

G

myosin light chain 12A

increases expression

fenamidone results in increased expression of MYL12A mRNA

NCBI chr 9:110,891,970...110,899,655
Ensembl chr 9:110,873,959...110,916,580

G

myosin light chain 9

increases expression

fenamidone results in increased expression of MYL9 mRNA

NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333

G

myoferlin

increases expression

fenamidone results in increased expression of MYOF mRNA

NCBI chr 1:235,673,666...235,822,413
Ensembl chr 1:235,673,666...235,822,334

G

Ngfi-A binding protein 2

increases expression

fenamidone results in increased expression of NAB2 mRNA

NCBI chr 7:63,497,589...63,504,105
Ensembl chr 7:63,497,589...63,503,989

G

NACC family member 2

increases expression

fenamidone results in increased expression of NACC2 mRNA

NCBI chr 3:8,879,952...8,946,660
Ensembl chr 3:8,883,065...8,946,660

G

nucleosome assembly protein 1-like 2

decreases expression

fenamidone results in decreased expression of NAP1L2 mRNA

NCBI chr X:68,174,051...68,176,449
Ensembl chr X:68,173,987...68,176,666

G

NSF attachment protein beta

decreases expression

fenamidone results in decreased expression of NAPB mRNA

NCBI chr 3:136,132,248...136,179,280
Ensembl chr 3:136,133,428...136,179,345

G

nuclear prelamin A recognition factor

decreases expression

fenamidone results in decreased expression of NARF mRNA

NCBI chr10:106,519,508...106,537,494
Ensembl chr10:106,519,444...106,537,486

G

NIMA-related kinase 6

increases expression

fenamidone results in increased expression of NEK6 mRNA

NCBI chr 3:22,284,269...22,356,302
Ensembl chr 3:22,284,279...22,395,990

G

nestin

increases expression

fenamidone results in increased expression of NES mRNA

NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777

G

neuropilin and tolloid like 1

decreases expression

fenamidone results in decreased expression of NETO1 mRNA

NCBI chr18:79,635,633...79,753,913
Ensembl chr18:79,635,633...79,749,030

G

nuclear factor kappa B subunit 2

increases expression

fenamidone results in increased expression of NFKB2 mRNA

NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213

G

nicotinamide nucleotide transhydrogenase

increases expression

fenamidone results in increased expression of NNT mRNA

NCBI chr 2:51,411,413...51,505,125
Ensembl chr 2:51,411,413...51,504,823

G

notch receptor 1

increases expression

fenamidone results in increased expression of NOTCH1 mRNA

NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531

G

notch receptor 3

increases expression

fenamidone results in increased expression of NOTCH3 mRNA

NCBI chr 7:11,132,984...11,184,025
Ensembl chr 7:11,133,706...11,184,025

G

natriuretic peptide receptor 2

increases expression

fenamidone results in increased expression of NPR2 mRNA

NCBI chr 5:57,883,171...57,901,590
Ensembl chr 5:57,883,171...57,901,580

G

NAD(P)H quinone dehydrogenase 1

increases expression
multiple interactions

fenamidone results in increased expression of NQO1 mRNA
sulforaphane inhibits the reaction [fenamidone results in increased expression of NQO1 mRNA]

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

neuregulin 1

increases expression

fenamidone results in increased expression of NRG1 mRNA

NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884

G

neurexin 3

decreases expression

fenamidone results in decreased expression of NRXN3 mRNA

NCBI chr 6:107,641,760...109,272,849
Ensembl chr 6:107,641,780...109,272,044

G

NUAK family kinase 2

increases expression

fenamidone results in increased expression of NUAK2 mRNA

NCBI chr13:43,753,454...43,770,604
Ensembl chr13:43,753,832...43,770,604

G

nucleoporin 93

increases expression

fenamidone results in increased expression of NUP93 mRNA

NCBI chr19:10,684,214...10,788,009
Ensembl chr19:10,682,075...10,788,026

G

neurexophilin 1

decreases expression

fenamidone results in decreased expression of NXPH1 mRNA

NCBI chr 4:36,998,068...37,311,135
Ensembl chr 4:36,997,669...37,311,132

G

neurexophilin 2

decreases expression

fenamidone results in decreased expression of NXPH2 mRNA

NCBI chr 3:5,986,175...5,988,525
Ensembl chr 3:5,756,621...5,987,008

G

osteoclast stimulating factor 1

increases expression

fenamidone results in increased expression of OSTF1 mRNA

NCBI chr 1:216,002,037...216,049,226
Ensembl chr 1:216,002,044...216,049,221

G

purinergic receptor P2Y2

increases expression

fenamidone results in increased expression of P2RY2 mRNA

NCBI chr 1:155,352,050...155,367,423
Ensembl chr 1:155,351,165...155,367,632

G

palladin, cytoskeletal associated protein

increases expression

fenamidone results in increased expression of PALLD mRNA

NCBI chr16:28,228,006...28,621,349
Ensembl chr16:27,981,354...28,621,337

G

poly (ADP-ribose) polymerase family, member 3

increases expression

fenamidone results in increased expression of PARP3 mRNA

NCBI chr 8:107,111,010...107,117,073
Ensembl chr 8:107,111,012...107,116,782

G

protocadherin 19

decreases expression

fenamidone results in decreased expression of PCDH19 mRNA

NCBI chr X:96,767,686...96,873,477
Ensembl chr X:96,771,947...96,873,524

G

phosphoenolpyruvate carboxykinase 2 (mitochondrial)

increases expression

fenamidone results in increased expression of PCK2 mRNA

NCBI chr15:29,027,891...29,036,729
Ensembl chr15:29,027,894...29,037,283

G

phosphate cytidylyltransferase 1B, choline

decreases expression

fenamidone results in decreased expression of PCYT1B mRNA

NCBI chr X:58,378,090...58,471,623
Ensembl chr X:58,378,116...58,468,935

G

platelet derived growth factor receptor beta

increases expression

fenamidone results in increased expression of PDGFRB mRNA

NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843

G

PDZ and LIM domain 2

increases expression

fenamidone results in increased expression of PDLIM2 mRNA

NCBI chr15:45,235,421...45,250,187
Ensembl chr15:45,237,477...45,249,242

G

PDZ and LIM domain 5

increases expression

fenamidone results in increased expression of PDLIM5 mRNA

NCBI chr 2:230,952,251...231,120,329
Ensembl chr 2:230,952,248...231,120,275

G

phosphoglucomutase 2-like 1

decreases expression

fenamidone results in decreased expression of PGM2L1 mRNA

NCBI chr 1:154,571,410...154,620,901
Ensembl chr 1:154,571,766...154,620,902

G

phosphoglycerate dehydrogenase

increases expression

fenamidone results in increased expression of PHGDH mRNA

NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944

G

pleckstrin homology-like domain, family A, member 3

increases expression

fenamidone results in increased expression of PHLDA3 mRNA

NCBI chr13:47,193,250...47,196,335
Ensembl chr13:47,193,086...47,196,335

G

pleckstrin homology-like domain, family B, member 2

increases expression

fenamidone results in increased expression of PHLDB2 mRNA

NCBI chr11:54,859,173...55,078,212
Ensembl chr11:54,859,135...55,078,467

G

phytanoyl-CoA 2-hydroxylase

increases expression

fenamidone results in increased expression of PHYH mRNA

NCBI chr17:73,329,461...73,346,359
Ensembl chr17:73,329,082...73,346,409

G

piezo-type mechanosensitive ion channel component 1

increases expression

fenamidone results in increased expression of PIEZO1 mRNA

NCBI chr19:50,544,580...50,606,812
Ensembl chr19:50,544,582...50,606,501

G

plasminogen activator, urokinase

increases expression

fenamidone results in increased expression of PLAU mRNA

NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775

G

phospholipase C beta 3

increases expression

fenamidone results in increased expression of PLCB3 mRNA

NCBI chr 1:204,143,257...204,160,384
Ensembl chr 1:204,144,956...204,160,228

G

pleckstrin homology domain containing A7

increases expression

fenamidone results in increased expression of PLEKHA7 mRNA

NCBI chr 1:170,364,524...170,547,843
Ensembl chr 1:170,365,135...170,547,775

G

pleckstrin homology and RhoGEF domain containing G2

increases expression

fenamidone results in increased expression of PLEKHG2 mRNA

NCBI chr 1:83,651,902...83,665,063
Ensembl chr 1:83,647,748...83,665,063

G

pleckstrin homology domain containing O2

increases expression

fenamidone results in increased expression of PLEKHO2 mRNA

NCBI chr 8:66,079,106...66,105,283
Ensembl chr 8:66,078,448...66,105,266

G

plexin B2

increases expression

fenamidone results in increased expression of PLXNB2 mRNA

NCBI chr 7:120,232,276...120,258,385
Ensembl chr 7:120,232,331...120,258,330

G

PML nuclear body scaffold

increases expression

fenamidone results in increased expression of PML mRNA

NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971

G

protein O-glucosyltransferase 3

increases expression

fenamidone results in increased expression of POGLUT3 mRNA

NCBI chr 8:53,777,614...53,795,404
Ensembl chr 8:53,777,785...53,795,399

G

protein phosphatase, Mg2+/Mn2+ dependent, 1E

decreases expression

fenamidone results in decreased expression of PPM1E mRNA

NCBI chr10:72,051,643...72,187,439
Ensembl chr10:72,055,208...72,187,282

G

protein kinase C, delta

increases expression

fenamidone results in increased expression of PRKCD mRNA

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

protein kinase C, gamma

decreases expression

fenamidone results in decreased expression of PRKCG mRNA

NCBI chr 1:65,832,851...65,860,676
Ensembl chr 1:65,832,855...65,859,384

G

protein kinase D1

increases expression

fenamidone results in increased expression of PRKD1 mRNA

NCBI chr 6:67,725,193...68,039,002
Ensembl chr 6:67,725,905...68,039,042

G

prion like protein doppel

increases expression

fenamidone results in increased expression of PRND mRNA

NCBI chr 3:119,213,462...119,218,742
Ensembl chr 3:119,213,429...119,218,745

G

serine protease 23

increases expression

fenamidone results in increased expression of PRSS23 mRNA

NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:143,401,396...143,422,091

G

protein tyrosine phosphatase, non-receptor type 13

increases expression

fenamidone results in increased expression of PTPN13 mRNA

NCBI chr14:6,108,202...6,282,619
Ensembl chr14:6,108,211...6,282,563

G

protein tyrosine phosphatase, non-receptor type 14

increases expression

fenamidone results in increased expression of PTPN14 mRNA

NCBI chr13:101,268,258...101,420,508
Ensembl chr13:101,268,416...101,414,088

G

protein tyrosine phosphatase, non-receptor type 21

increases expression

fenamidone results in increased expression of PTPN21 mRNA

NCBI chr 6:117,933,066...117,998,095
Ensembl chr 6:117,933,066...117,998,095

G

PTTG1 regulator of sister chromatid separation, securin

increases expression

fenamidone results in increased expression of PTTG1 mRNA

NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837

G

pentraxin 3

increases expression

fenamidone results in increased expression of PTX3 mRNA

NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323

G

RAB3B, member RAS oncogene family

decreases expression

fenamidone results in decreased expression of RAB3B mRNA

NCBI chr 5:123,629,562...123,697,410
Ensembl chr 5:123,644,423...123,697,401

G

RE1-silencing transcription factor

increases expression

fenamidone results in increased expression of REST mRNA

NCBI chr14:30,859,109...30,879,828
Ensembl chr14:30,862,553...30,894,354

G

regulator of G-protein signaling 7 binding protein

decreases expression

fenamidone results in decreased expression of RGS7BP mRNA

NCBI chr 2:36,133,944...36,231,505
Ensembl chr 2:36,139,201...36,231,505

G

rhomboid 5 homolog 2

increases expression

fenamidone results in increased expression of RHBDF2 mRNA

NCBI chr10:101,833,157...101,860,283
Ensembl chr10:101,833,157...101,860,283

G

ras homolog family member C

increases expression

fenamidone results in increased expression of RHOC mRNA

NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306

G

ras homolog family member D

increases expression

fenamidone results in increased expression of RHOD mRNA

NCBI chr 1:201,708,699...201,724,405
Ensembl chr 1:201,708,699...201,722,632

G

ras homolog family member G

increases expression

fenamidone results in increased expression of RHOG mRNA

NCBI chr 1:156,618,713...156,630,710
Ensembl chr 1:156,615,349...156,631,257

G

ribosomal modification protein rimK-like family member A

decreases expression

fenamidone results in decreased expression of RIMKLA mRNA

NCBI chr 5:133,072,179...133,098,840
Ensembl chr 5:133,073,960...133,098,792

G

rabphilin 3A

decreases expression

fenamidone results in decreased expression of RPH3A mRN